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ABSTRACT 
Hypertension, the leading global risk factor for early mortality, can not be detected 
or treated without accurate and practical methods of BP measurement. Although 
home blood pressure (BP) measurement enjoys considerable popularity among 
patients, the lack of evidence needed to assure its place in modern clinical practice 
has hindered its widespread acceptance among physicians. The objective of this 
study was to show that home BP measurement is more accurate than conventional 
clinic BP measurement and can be used effectively in clinical practice. We assessed 
the use of home BP for diagnosing hypertension and guiding antihypertensive 
treatment. The association between home BP and hypertensive end-organ damage 
was also examined. 
The first study population consisted of a representative sample of the Finnish adult 
population (2 120 individuals aged 45–74 years). These subjects underwent a 
clinical interview, electrocardiography and measurement of clinic and home BP. 
Carotid intima-media thickness (an indicator of atherosclerosis) and arterial pulse 
wave velocity (an indicator of arterial stiffness) were also measured in two subsets 
of 758 and 237 subjects, respectively. In a second study cohort, consisting of 98 
hypertensive patients, adjustment of antihypertensive treatment was randomized to 
either daytime ambulatory BP or home diastolic BP. 
Clinic BP was significantly higher than home BP (mean systolic/diastolic difference 
was 8/3 mmHg), and the overall agreement between the two methods in diagnosing 
hypertension was moderate at best (75%). Of 593 subjects with elevated clinic BP, 
38% had normal BP at home; so called white-coat hypertension. Hypertension could 
therefore be overdiagnosed in every third patient in a clinical screening situation. 
White-coat hypertension was associated with mildly elevated clinic BP, lower body 
mass index and non-smoking status, but not with psychiatric disease. However, the 
cardiovascular risk profile of white-coat hypertensives was between that of the 
normotensives and sustained hypertensives, indicating that white-coat hypertension 
is not a completely benign phenomenon, and may be a precursor of true 
hypertension. Home BP was more closely associated with hypertensive end-organ 
damage (intima-media thickness, pulse wave velocity, and electrocardiographic 
 evidence of left ventricular hypertrophy) than was clinic BP. The adjustment of 
antihypertensive treatment based on home BP measurement is effective as it led to 
equally good BP control as did ambulatory BP monitoring, which has been 
considered by many as the gold standard. 
On the basis of these results and data from previous studies, it can be concluded that 
home BP measurement is an improvement over conventional clinic BP 
measurement. Home monitoring of BP is as a convenient, accurate, and widely 
available option and may become the method of choice when diagnosing and 
treating hypertension. A paradigm shift is needed in BP measurement as evidence-
based medicine suggests that clinic BP measurement should only be used for 
screening purposes. 
 
Keywords: Hypertension, blood pressure, blood pressure determination, home blood 
pressure monitoring, epidemiology 
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TIIVISTELMÄ 
Kohonnutta verenpainetta, maailmanlaajuisesti merkittävintä ennenaikaiselle 
kuolemalle altistavaa riskitekijää, ei voida tunnistaa tai hoitaa ilman tarkkoja ja 
käytännöllisiä verenpaineen mittausmenetelmiä. Verenpaineen kotimittaus on 
saavuttanut suuren suosion potilaiden keskuudessa. Lääkärit eivät ole kuitenkaan 
vielä täysin hyväksyneet verenpaineen kotimittausta, sillä riittävä todistusaineisto 
sen toimivuudesta ja eduista on puuttunut. Tämän tutkimuksen tarkoituksena oli 
osoittaa, että kotona mitattu verenpaine (kotipaine) on perinteistä vastaanotolla 
mitattua verenpainetta (vastaanottopaine) tarkempi, ja että se on tehokas myös 
kliinisessä käytössä. Tutkimme kotipaineen käyttöä verenpainetaudin 
diagnosoinnissa ja hoidossa. Lisäksi tarkastelimme kotipaineen yhteyttä 
verenpainetaudin aiheuttamiin kohde-elinvaurioihin. 
Ensimmäinen aineisto, joka oli edustava otos Suomen aikuisväestöstä, koostui 2 120 
45–74-vuotiaasta tutkimushenkilöstä. Tutkittavat mittasivat kotipainettaan viikon 
ajan ja osallistuivat terveystarkastukseen, johon sisältyi kliinisen tutkimuksen ja 
haastattelun lisäksi sydänfilmin otto ja vastaanottopaineen mittaus. 758 tutkittavalle 
suoritettiin lisäksi kaulavaltimon seinämän intima-mediakerroksen paksuuden 
(valtimonkovettumataudin mittari) mittaus ja 237:lle valtimon pulssiaallon 
nopeuden (valtimojäykkyyden mittari) mittaus. Toisessa aineistossa, joka koostui 98 
verenpainetautia sairastavasta potilaasta, hoitoa ohjattiin satunnaistamisesta riippuen 
joko ambulatorisen eli vuorokausirekisteröinnillä mitatun verenpaineen tai 
kotipaineen perusteella. 
Vastaanottopaine oli kotipainetta merkittävästi korkeampi (systolisen/diastolisen 
paineen keskiarvoero oli 8/3 mmHg) ja yksimielisyys verenpainetaudin diagnoosissa 
kahden menetelmän välillä oli korkeintaan kohtalainen (75 %). 593 tutkittavasta, 
joilla oli kohonnut verenpaine vastaanotolla, 38 %:lla oli normaali verenpaine 
kotona eli ns. valkotakkiverenpaine. Verenpainetauti voidaan siis ylidiagnosoida 
joka kolmannella potilaalla seulontatilanteessa. Valkotakkiverenpaine oli yhteydessä 
lievästi kohonneeseen verenpaineeseen, matalaan painoindeksiin ja 
tupakoimattomuuteen, muttei psykiatriseen sairastavuuteen. Valkotakkiverenpaine 
ei kuitenkaan vaikuttaisi olevan täysin vaaraton ilmiö ja voi ennustaa tulevaa 
verenpainetautia, sillä siitä kärsivien sydän- ja verisuonitautien riskitekijäprofiili oli 
 normaalipaineisten ja todellisten verenpainetautisten riskitekijäprofiilien välissä. 
Kotipaineella oli vastaanottopainetta vahvempi yhteys verenpainetaudin 
aiheuttamiin kohde-elinvaurioihin (intima-mediakerroksen paksuus, pulssiaallon 
nopeus ja sydänfilmistä todettu vasemman kammion suureneminen). Kotipaine oli 
tehokas verenpainetaudin hoidon ohjaaja, sillä kotipaineeseen ja ambulatoriseen 
paineeseen, jota on pidetty verenpainemittauksen ”kultaisena standardina”, 
perustuva lääkehoidon ohjaus johti yhtä hyvään verenpaineen hallintaan. 
Tämän ja aikaisempien tutkimusten tulosten pohjalta voidaan todeta, että 
verenpaineen kotimittaus on selkeä parannus perinteiseen vastaanotolla tapahtuvaan 
verenpainemittaukseen verrattuna. Verenpaineen kotimittaus on käytännöllinen, 
tarkka ja laajasti saatavilla oleva menetelmä, josta voi tulla jopa ensisijainen 
vaihtoehto verenpainetautia diagnosoitaessa ja hoitaessa. Verenpaineen 
mittauskäytäntöön tarvitaan muutos, sillä näyttöön perustuvan lääketieteen 
perusteella vaikuttaa, että vastaanotolla tapahtuvaa verenpainemittausta tulisi käyttää 
vain seulontatarkoitukseen. 
 
Avainsanat: Verenpainetauti, verenpaine, verenpaineen mittaus, verenpaineen 
kotimittaus, epidemiologia 
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ABBREVIATIONS 
ANOVA Analysis Of Variance 
ARIC Atherosclerosis Risk in Communities 
BDI Beck Depression Inventory 
BMI Body Mass Index 
BP  Blood Pressure 
ECG  Electrocardiography/electrocardiogram 
ECG-LVH Electrocardiographic evidence of Left Ventricular 
Hypertrophy 
ESH  European Society of Hypertension 
GHQ-12 12-item General Health Questionnaire 
HDL High Density Lipoprotein 
ICH  Isolated Clinic Hypertension 
IMT  Intima-Media Thickness 
LDL Low Density Lipoprotein 
PAMELA Pressioni Arteriose Monitorate E Loro 
Associazioni 
PWV Pulse Wave Velocity 
TAS-20 20-item Toronto Alexithymia Scale 
Whiteley-7 7-item Whiteley index 
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1 INTRODUCTION 
A few risk factors account for a large contribution to global loss of healthy life. 
Overall, 26% of the worldwide adult population had high blood pressure (BP) i.e. 
hypertension (clinic BP ≥ 140 mmHg systolic and/or 90 mmHg diastolic) in 2000 
and 29% are projected to have this condition in 2025 [1]. Hypertension has been 
identified as the third most important cause for global burden of disease and as the 
leading global risk factor for mortality, accounting for over 7 million deaths yearly 
[2]. The risks of high BP are not only limited to those with severe hypertension, as 
there is a continuous relationship with cardiovascular risk even throughout the 
normal range of usual BP (down at least as far as 115/75 mmHg). Lowering of the 
systolic BP by only 10 mmHg, or lowering the diastolic BP by only 5 mmHg would, 
in the long term, be associated with a lower risk (about 40%) of stroke death and a 
lower risk (about 30%) of death from ischemic heart disease or other vascular causes 
throughout middle age [3]. In Finland, mean BP has decreased significantly during 
the past 30 years, but hypertension care is still far from optimal as only 20 to 30% of 
treated hypertensives have adequately controlled BP [4, 5]. Hypertension is indeed 
an important public health challenge worldwide and prevention, detection, 
treatment, and control of this condition should receive high priority. 
BP, however, can not be prevented, detected, treated nor controlled without accurate 
and practical methods of BP measurement. If proper methods are not used, inexact 
BP measurement can lead to poor diagnostic accuracy, unnecessary costs and 
therapy, and poor medical treatment. Despite several limitations, measurement of 
BP has until recently occurred primarily at the physician’s office using a stethoscope 
and a conventional mercury sphygmomanometer. Only during the past decade have 
techonogical advances provided novel options for measuring BP, such as home 
monitoring, which is becoming increasingly popular world-wide [6]. 
One of the reasons why home BP measurement has not received widespread 
acceptance in the minds of physicians, despite its considerable popularity with 
patients, is a lack of evidence needed to assure its place in modern clinical practice. 
This thesis was planned to provide physicians with evidence that home BP 
measurement can be used effectively in clinical practice, and that it offers clear 
benefits compared with conventional clinic measurement. 
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2 REVIEW OF THE LITERATURE 
2.1 History of home blood pressure measurement 
The standard method of indirect measurement of BP is based on the principle of 
arterial occlusion and BP detection by various techniques, the first of which of was 
palpation, described by Scipione Riva-Rocci in 1896 [7]. In 1905, Nikolai Korotkoff 
improved Riva-Rocci’s method when he recognized that by placing a stethoscope 
over the brachial artery at the cubital fossa, distal to a Riva-Rocci cuff, tapping 
sounds could be heard as the cuff was deflated, caused by blood flowing back into 
the artery. Korotkoff concluded correctly that the appearance of the tapping sounds 
coincided with systolic BP and the disappearance of the sounds with diastolic BP 
[8]. The method of BP measurement invented by Korotkoff quickly received wide 
recognition and became a standard medical procedure. His technique has truly stood 
the test of time as it has been used for more than a century with practically no 
alterations [9]. 
Brown was the first to report that BP measured in the home was lower than that 
recorded by a doctor [10]. Ayman and Goldshine proposed the concept of “self BP 
measurement” in 1940 and also concluded that BP measured at home was lower 
than clinic BP [11]. Ayman and Goldshine were also clearly ahead of their time, as 
they suggested that home BP monitoring was useful for (1) instructing the patients 
about their chronic disease, (2) teaching physicians about the natural course of the 
disease and about factors that affect the disease, (3) learning the prognosis of 
disease, and (4) increasing the precision of determining the effectiveness of 
treatment, as all of these hypotheses are slowly being proved correct [11]. However, 
self-measurement was initially performed using Korotkoff’s auscultation method 
and remained a rarity for many decades due to its complex nature. In the mid-1970s, 
the first automated sphygmomanometers based on the auscultatory technique 
became available, but were not widely distributed because of high price and 
mechanical problems [12]. Development of the Dinamap, the first commercial 
oscillometric device for BP measurement begun in the early 1970s and it was first 
offered for sale in 1976 [13]. When simple and small automated devices based on 
the cuff-oscillometric method were presented in the 1980s, the popularity of home 
BP measurement exploded and has seen exponential growth ever since [6]. 
Currently home BP monitors are becoming ever smaller and are being embedded 
with additional features such as printers, PC connections, long-term tracking 
memories for morning and evening measurements, and the ability to detect an 
irregular heart beat.  
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In 1994 the American Heart Association estimated that $126 million was spent on 
home BP monitors in the United States alone [14]. By now, the world market for 
home-use digital BP monitors has grown to be worth almost $800 million [6]. The 
gradual ageing of the world population combined with the increasing prevalence of 
hypertension will probably provide an increasing potential market. The predicted 
rise of telehealth will add even greater value to the market, which is forecast to grow 
at 6.7% per year, taking it to over $1 billion by 2010 [6]. 
2.2 Measuring home blood pressure 
2.2.1 Blood pressure as a physiological phenomenon 
Unfortunately, BP is not a constant variable and significant spontaneous variation in 
BP occurs, which complicates its measurement. Intra-arterial beat-to-beat BP 
monitoring in ambulatory subjects has shown that BP values may vary by more than 
50–60 mmHg over 24 hours [15]. These variations originate from short-lasting 
pressor and depressor episodes that give BP recording a typical unstable appearance 
even over short periods in immobilized patients. BP is a hemodynamic phenomenon 
that is affected by respiration, emotion, exercise, meals, tobacco, alcohol, 
temperature, bladder distension, and pain [16, 17].  
BP variation also largely originates from the diurnal variation of BP characterized 
by a substantial reduction during sleep, which has been known for over a century 
[18]. A seminal study by Millar-Craig et al. showed by using continuous intra-
arterial measurements that BP is highest mid-morning and then falls progressively 
throughout the rest of the day; in addition, BP is lowest at night (nocturnal dip), but 
rises before awakening (morning surge) [19]. These findings highlighted the 
importance of the circadian rhythm of BP with regard to management of 
hypertension. BP also seems to vary between months and seasons, as BP is lower 
during the summer period and higher in winter [20]. 
It is not always possible to modify all the factors that affect BP variability, but it is 
possible to take them into account in reaching a decision as to the relevance of a 
single BP measurement often acquired at the clinic. Although clinic BP predicts 
increased cardiovascular risk to some extent on the population level, many patients 
with high clinic BP will not experience cardiovascular events [21]. This finding may 
be explained partly by the fact that isolated BP measurements made during clinic 
visits give only a very limited number of measurements, and no information of the 
diurnal variation of BP. These problems, however, can be addressed with more 
modern BP measurement methods, such as home and ambulatory BP measurement.  
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2.2.2 Devices and validation 
Currently, nearly all the automated devices used for home BP measurement use the 
oscillometric technique. The fundamental concept underlying these devices is the 
same as that of other cuff-based BP measuring devices, in that compression of the 
brachial artery by an inflatable cuff allows indirect determination of the intra-arterial 
vascular pressure. However, the physiological differences among the various 
devices can be potentially quite large as the auscultatory method relies on the 
association between Korotkoff sounds and systolic and diastolic BP, whereas the 
oscillometric technique uses the small oscillations in cuff pressure to identify the 
systolic, mean, and diastolic pressures [22]. Another difference is that in 
oscillometric devices cuff inflation and deflation are automated and that BP 
determination is made by a microprocessor using information sent to it from a 
pressure transducer.  
The precise technique of automated oscillometric BP measurement varies greatly 
from one device to another. In general, the BP cuff is inflated to between 160 and 
180 mmHg for the first BP determination, or approximately 30 mmHg above the 
previously measured systolic BP. After a brief holding period, and if no oscillations 
are detected, the cuff pressure is reduced slowly in a discontinuous or continuous 
manner, depending upon the specific device. As the cuff pressure decreases, 
oscillations of the arterial wall increase in amplitude and reach a maximum when the 
cuff pressure is at mean arterial pressure. With further deflation the oscillations start 
to diminish. The mean BP is determined at the peak of the amplitude of the 
oscillations; the systolic BP, approximately 55% prior to the maximum; and the 
diastolic BP, approximately 85% after the maximum oscillations (Figure 1). The 
monitor then displays these BP values for the user [22]. However, the exact points of 
BP determinations and algorithms used by the devices are considered proprietary 
information by the manufacturers, making it impossible for investigators to verify 
the accuracy of their underlying physiological principle [23]. 
The sale and marketing of electronic BP monitors is currently not, nor has ever been, 
subject to any medical influence. Even in the early days of home BP measurement it 
was noticed that this freedom from medical control quickly resulted in the 
manufacture and marketing of a vast array of devices with poor accuracy, which few 
were validated in any way [24]. With this in mind, the Association for the 
Advancement of Medical Instrumentation (AAMI) published the first standard for 
electronic or aneroid sphygmomanometers in 1987 that included a protocol for 
evaluating the accuracy of devices [25]. Thereafter several other European, British, 
and North American protocols followed, but currently the European Society of 
Hypertension (ESH) International Protocol is most commonly used for validation of 
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BP measuring devices [26-28]. Hypertension guidelines and societies recommend 
the exclusive use of validated home monitors in clinical practice, although such 
validation is still not mandatory [29, 30]. Home-monitoring devices should also be 
checked for accuracy every 1–2 years. 
 
Figure 1. Oscillomteric technique compared with the auscultatory technique for 
measurement of blood pressure. As indicated auscultatory systolic blood 
pressure; Am auscultatory mean blood pressure; and Ad auscultatory 
diastolic blood pressure. Reproduced with permission from Biomedical 
Instrumentation and Technology [23] . 
After the development of accuracy standards, a report assessed compliance with the 
guidelines. In 1989, of 23 monitors that underwent validation, only 12 (52%) met 
AAMI standards for diastolic accuracy and 39% of the devices met both systolic and 
diastolic standards [31].  Afterwards, validated BP measuring devices have been 
assessed in the literature from time to time, but as such surveys soon become 
outdated, up-to-date information can currently be easily found from the Internet site 
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of a non-profit organization [32]. Although validation protocols for home BP 
monitors have existed already for two decades and information of validated devices 
can be easily found, the state of the market is still poor. In 2003 only 53% of the 
Internet sites selling home BP monitors offered validated devices and only 9% of 
these sites mentioned device validation [33]. 
Different types of home BP monitors are also available. Upper arm devices are 
currently recommended, while the use of finger and wrist devices is discouraged 
[29, 30]. Devices that measure BP from a finger are not recommended, because of 
the inaccuracies caused by measurement distortion from peripheral vasoconstriction, 
the greater alteration in BP at more distal the sites of recording, and the effect of 
limb position on BP [26]. Although quite popular, wrist monitors are subject to the 
same latter two problems as the finger devices [34, 35]. Most of the wrist devices 
have not passed independent validation, [36, 37] although some newer monitors 
have been recommended [38-40]. Measurements are affected by anatomical factors, 
such as wrist anatomy and dorsal or ulnar flexion of the wrist [36]. Furthermore, if 
the wrist is not held at heart level, inaccurate measurements will be obtained [36]. 
Recently, to overcome this problem, wrist home BP devices with position sensors 
have been developed, but their performance still needs further analysis until wrist 
monitors can be recommended [38-40]. In the future, home telemonitoring of 
hypertension could also be a promising patient management approach, but more 
studies are needed to accummulate evidence related to its clinical effects and cost 
effectiveness [41]. 
2.2.3 Optimal scheme for home blood pressure measurement 
The recommendations for performing home BP measurement do not vary in 
principle from those that apply to BP measurement in general: there should be a 
short period of rest before measurement, the arm should be supported with the cuff 
at the level of the heart, and a cuff of proper size should be used [30, 42, 43]. 
However, perfect consensus still does not exist on how many daily measurements 
and for how many days should be performed when measuring BP at home to obtain 
the best assessment of the actual BP levels in a given subject. The current ESH 
guidelines recommend two measurements in the morning and two measurements in 
the evening for one week with the exclusion of measurements from the first day 
[42]. However, the North American guidelines advise taking three readings on one 
occasion every morning and evening, but do not mention for how many days [30]. 
These conflicting guidelines only demonstrate that agreement on this matter has not 
yet been reached. Two methods have been used to define the most suitable schedule 
for home BP measurement, a statistical and a clinical approach [44]. 
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In the statistical method, the criteria for defining the best frequency of home BP 
measurements should be based on (1) the reproducibility of home BP values 
obtained, (2) their stability over time, and (3) their relation to the average 
ambulatory BP values, the latter being considered the gold standard references [42, 
45]. Chatellier et al. concluded that the maximal reduction in the standard deviation 
in the difference between two mean BP values was obtained when each mean was 
defined by 30 measurements (three measurements for ten consecutive days). 
However, 80% of this maximal reduction was already obtained with mean values 
defined by 15 measurements (three measurements collected over five days) [46]. 
This conclusion was supported by the results of the SMART study, which also 
showed that only a small decrease in the standard deviation of the mean difference 
in average home BP values between two sessions is achieved after six home BP 
measurements [47]. Two studies by Stergiou et al. also concluded that at least 12 
measurements taken on three days are needed for the reproducibility of home BP to 
be superior to that of office measurements [48, 49]. On the other hand, Brook 
reported that if the accuracy of the average home BP was determined by agreement 
with average ambulatory BP values, the total number of measurements and the total 
duration of monitoring were not important and that most benefits could be achieved 
by obtaining as few as two home BP measurements on one day [50].  
Prognostic clinical data is, of course, a more suitable method than statistical methods 
for defining the best amount of BP measurements needed. Recent follow-up studies 
have shown that even two home BP measurements are able to predict the risk of 
cardiovascular events [51, 52]. However, only Ohkubo et al. have tried to identify 
the best frequency of home BP measurements based on prognostic data from the 
community-based Ohasama study [53]. They reported that the predictive value for 
the risk of stroke increases progressively without any threshold if the number of 
measurements was increased from 1 to 14. In any case, whether the statistical or 
clinical approach is used for determining an optimal BP measurement schedule, it 
appears that the advantages of home BP measurement depend not only on the 
statistical advantages associated with the availability of repeated measurements, but 
also in obtaining information out of the clinical setting with even a few home BP 
measurements [53, 54]. 
The differences in morning and evening home BP in the general population appear 
to be quite small, under 2 mmHg [55, 56]. However, in treated hypertensives, trough 
morning home BP measurements and evening measurements can be used effectively 
for assessing the duration of antihypertensive drug action in patients [57, 58]. 
Measuring home BP in the morning and evening is therefore sensible, and also 
recommended by the guidelines [30, 42]. 
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Higher and unstable values are usually obtained during the first home BP 
measurements and current ESH guidelines therefore recommend discarding home 
BP measurements from the first day [49, 53, 59]. Two or three measurements on 
each occasion are also recommended, although the two largest epidemiological 
studies have been performed with just one BP measurement on each occasion [30, 
42, 52, 60]. However, no clear prognostic evidence yet exists to support either of 
these recommendations. 
2.3 Diagnosing hypertension with home blood pressure 
2.3.1 Reference values for home blood pressure measurement 
All major epidemiological studies are primarily based on clinic BP measurements, 
which therefore is still the criterion standard for determining hypertension-related 
morbidity and mortality. Therefore it is extremely important to know whether 
differences between home and clinic BP exist. In untreated subjects, home BP is, on 
average, 7–8/5–6 mmHg lower than clinic BP and in treated subjects 5/3 mmHg 
lower than clinic BP [61, 62]. The difference between systolic home and clinic BP 
also appears to slightly increase with higher BP [61]. As a result, home and clinic 
BP are not directly comparable and separate diagnostic thresholds are needed for 
both. Data from ambulatory BP measurement are often reported as 24-hour daytime 
and night-time averages. Since home BP is usually measured at daytime, the 
daytime ambulatory average should be used for comparisons. In a meta-analysis 
with over 4000 subjects, the difference between daytime ambulatory BP and home 
BP was only -1.2/1.2 mmHg, which is clinically insignificant [62]. The 
reproducibility of home and ambulatory BP values is also better than that of clinic 
BP [63]. 
Home BP measurement should be distinguished from self-measurement of BP, 
which can occur in places other than home, such as at the worksite or in the 
community (e.g. the local health center or pharmacy), as different settings may give 
different readings. Self-measurement at the clinic has not been shown to eliminate 
the white-coat effect as two studies have reported no significant difference between 
self- and physician-measured BP in the clinic [64, 65]. Home readings taken by self 
versus a relative also appear to be almost identical [64]. 
The classification of BP is still mainly based on clinic BP values in all current major 
guidelines [29, 43, 66]. In addition to defining hypertension, most guidelines also 
give several subcategories for normotensives and hypertensives (Table 1) [29, 43, 
66]. The problem with classifying BP is that it is a continuous variable, and risks of 
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various associated adverse outcomes rise as BP rises, without any clear threshold 
[3]. However, despite these problems, thresholds are needed for everyday clinical 
practice. One must still remember that the diagnostic thresholds are arbitrary and 
subjective, and also vary from one recommendation to another [29, 43, 66].  
 
Table 1. Definitions and classification of clinic blood pressure  levels 
 Classification according to guideline 
 BP Level (mmHg) Europe United States Finland 
< 120/80 Optimal Normal Optimal 
120–129/80–84 Normal Prehypertension Normal 
130–139/85–89 High Normal Prehypertension Satisfactory 
140–159/90–99 Grade 1 HT Stage 1 HT Mildly elevated 
160–179/100–109 Grade 2 HT Stage 2 HT Moderately elevated 
≥ 180/≥ 110 Grade 3 HT Stage 2 HT Markedly elevated 
BP, blood pressure; HT, hypertension. 
 
Widespread clinical use of home BP measurement was first limited by the lack of a 
generally accepted reference frame and operational thresholds for initiating 
treatment. Before prognostic data were available, home BP thresholds were defined 
from cross-sectional observations using different statistical criteria, such as the 
normal distribution criterion, percentile criterion, or regression criterion. In 1998, a 
meta-analysis of 17 population-based studies with 5422 untreated subjects suggested 
that a home BP ≥ 135/85 mmHg should be considered hypertensive (equivalent to a 
clinic BP ≥ 140/90 mmHg) which was quickly adopted by the guidelines [29, 30, 43, 
67]. However, normal BP should be preferably defined in terms of cardiovascular 
risk. So far, only one study has suggested threshold values for home BP based on 
outcome data. The Ohasama investigators proposed a reference value of 137/84 
mmHg for hypertension, which luckily was in line with the reference values 
obtained from the cross-sectional studies [68]. At the moment, all major guidelines 
concur with the idea that home BP levels < 135 mmHg systolic and 85 mmHg 
diastolic are normal, although even with these thresholds the agreement between 
clinic and home BP in diagnosing hypertension is moderate at best [29, 30, 42, 66, 
69, 70]. Further prospective studies are therefore needed to establish with more 
certainty the normal range of the self-measured home BP. 
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2.3.2 Isolated clinic (“white coat”) hypertension 
In 1983, Mancia used a continuous intra-arterial recorder to measure BP in the 
periods during which a doctor repeatedly measured BP by the cuff method [71]. He 
observed that in almost all normotensive and hypertensive subjects tested the 
doctor’s arrival at the bedside induced immediate rises in systolic and diastolic BP 
peaking within 1–4 minutes (mean 27/15 mmHg above pre-visit values). After the 
peak response BP declined and at the end of the visit was only slightly above the 
pre-visit level. This was the first recognition of the phenomenon known as the 
“white-coat effect”, a transient elevation in BP due to an alerting reaction 
characterized by a behaviour of the adrenergic nervous system that causes muscle 
sympathoinhibition and skin sympathoexcitation [72]. Mancia also demonstrated 
that the white-coat effect cannot be avoided by repeated measurements by a 
physician over a short time span, but can be reduced by over 40 %, however, if BP 
measurements are performed by a nurse [73]. The white-coat effect leads to poor 
diagnostic accuracy and is one of the main shortcomings of clinic BP measurement. 
Some patients have a persistently elevated clinic BP while their ambulatory or home 
BP is within normal range. This condition is widely known as “white-coat 
hypertension” [74], although the ESH guidelines suggest a more descriptive term 
“isolated clinic hypertension” (ICH) be used. This is because at least the difference 
between ambulatory and clinic BP does not seem to be strongly associated with the 
clinic BP elevation induced by the alerting reaction to a doctor or a nurse, which is 
the true white coat effect [75]. Instead, the white-coat effect appears to be associated 
with greater BP reactivity to psycho-social stimuli, such as public speaking [76]. 
ICH should be diagnosed whenever clinic BP is repeatedly ≥ 140/90 mmHg, while 
home BP is within normal range (< 135/85 mmHg). Its diagnosis can also be based 
on 24-hour mean and daytime BP, bearing in mind that subjects with ICH diagnosed 
with home BP may not be entirely the same group identified by ambulatory BP 
measurements [77, 78]. Automated serial BP measurement in a clinic setting has 
also been successfully used to identify patients with ICH, but no reference values 
exist yet for this method of measurement [79]. Depending on the definition of ICH 
and the characteristics of the study cohort, its prevalence can range from 11–17% in 
the general population [78, 80, 81] to 10–60% of the patients with elevated clinic BP 
[74, 82-88]. 
Data allowing an estimate of the probability of ICH are very scarce [74, 80, 84, 86], 
and nearly all of the previous studies have been performed using ambulatory BP 
monitoring in hypertension clinics or academic settings, and used selected patient 
materials. Furthermore, the findings have often been conflicting or non-significant. 
Overall, the previous data indicate that, in untreated hypertensive subjects, the 
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probability of ICH might increase with female sex, non-smoking status, a low body 
mass index (BMI) and mildly elevated clinic BP levels [74, 80, 84, 86]. Very little 
attention has been focused on the possible psychological determinants of ICH, 
although ICH is considered to be a consequence of the white-coat effect. There is 
some evidence that ICH might be associated with suppression of emotion [89], but 
not necessarily with anxiety or depression [89-91]. However, the findings of these 
studies with a limited number of patients have also been conflicting. Several studies 
have examined whether sympathetic overactivity exists in ICH, but the results have 
been variable, with sympathetic activity suggested as being increased [92, 93] or 
normal [94]. 
Several authors have concluded that in individuals with ICH the cardiovascular risk 
is nearly identical to those who have normal BP [81, 82, 87, 95-97]. However some 
[98, 99], although not all studies [83, 100, 101], have reported this condition to be 
associated with a prevalence of organ damage and metabolic abnormalities greater 
than that of normotensive subjects, which suggest that it may not be a clinically 
innocent phenomenon. It has also been suggested that patients with ICH initially 
have a low short-term incidence of stroke, but later on develop an increased risk for 
stroke as compared with patients with sustained hypertension [102]. The clinical 
significance of ICH has therefore been somewhat unclear. However, recent larger 
population studies have elucidated the prognosis of ICH to some extent, as they have 
demonstrated that the cardiovascular risk of individuals with ICH appears to be 
intermediate between that of subjects in whom normal BP and hypertension are 
found both in and out of office [51, 103]. 
Although much attention has been focused on ICH, there is still debate in the 
scientific community as to whether it truly is a distinct clinical entity, especially 
when dealing with large epidemiological data and not with a single patient who is 
visibly anxious over BP measurements. For example, the reproducibility of ICH is 
not good as 42–61% of the patients initially classified as having ICH with 
ambulatory measurement can no longer be classified as such from repeated 
monitoring [99, 104]. The major determinant of ICH also appears to be mildly 
elevated hypertension [83, 86]. Therefore ICH could be due to selection bias 
resulting from subjects having a BP level close to the diagnostic thresholds, as 
proposed by some [99, 105]. The fact that the cardiovascular risk and BP level of 
individuals with ICH appears to be intermediate between normotensives and 
sustained hypertensives, and that a large portion of subjects with ICH show a 
spontaneous progression towards true hypertension also support this assumption [51, 
103, 106]. 
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2.3.3 Masked hypertension 
Approximately 20 years after the discovery of the white coat effect, attention was 
drawn to a fourth group of patients in addition to those with sustained normotension, 
sustained hypertension and ICH. This group of patients has a normal clinic BP but 
an elevated ambulatory or home BP [107]. This phenomenon, which has also been 
previously observed in Finnish patients,  was dubbed “masked hypertension”, and it 
quickly gained widespread use [107-109]. The prevalence of masked hypertension 
appears to approximately same as for ICH in the general population [103]. Masked 
hypertension should be diagnosed whenever home BP or 24-hour mean/daytime 
ambulatory BP is ≥ 135/85 mmHg, while clinic BP is within normal range (< 140/90 
mmHg). Home-measured BP also appears to be an appropriate method for assessing 
masked hypertension, as similar proportions of subjects with masked hypertension 
are detected by ambulatory and home BP monitoring, although slight disagreement 
exists between the two methods [110]. 
Masked hypertension, determined with ambulatory BP measurement, has been 
associated with end-organ damage, such as increased left ventricular mass, carotid 
intima-media thickness (IMT), pulse wave velocity (PWV) and urinary albumin 
level [108, 111-113]. The risk for cardiovascular events also is higher for patients 
with masked hypertension than for subjects with normal clinic and ambulatory BP, 
but lower than for those with sustained hypertension [51, 81, 87, 103]. 
The concept of masked hypertension, like ICH, has several weaknesses. Again, as 
for ICH, the major determinant for masked hypertension appears to be a BP level 
close to the diagnostic thresholds [51, 114], and two studies that have examined the 
persistence of masked hypertension with repeated ambulatory measurement found 
reproducibility rates of only 38% and 72%, respectively [104, 115]. In 4 repeated 
home measurements performed on hypertensive patients, 50% had masked 
hypertension during the entire study, while only 2% consistently had masked 
hypertension on each visit [116]. It is therefore quite likely that patients with masked 
hypertension are mildly hypertensive patients with normal BP variation around the 
mean. Some authors have even compared the concept of masked hypertension to 
“statistical gymnastics” as a patient who has BP of 138/88 mmHg at home and in the 
clinic would have masked hypertension. [117]. Furthermore, the clinical significance 
of masked hypertension remains quite unclear as “unmasking” these masked patients 
would necessitate performing ambulatory or home BP monitoring on subjects who 
appear to have normal BP. 
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2.4 Home blood pressure measurement and the management of 
hypertension 
A recent meta-analysis of 18 randomised controlled trials by Cappuccio et al. 
showed that in the general healthcare system, hypertensive subjects using home BP 
measurement had 4.2/2.4 mmHg (2.2/1.9 mmHg after publication bias was allowed 
for) lower BP values and were more likely to achieve their target BP value than 
subjects without home measurement [118]. The reasons for this finding are still 
somewhat unclear. Part of this may be explained by the fact that home BP 
measurement is the most acceptable method for patients, when compared to 
ambulatory monitoring, measurement by a doctor or a nurse, or self-measurement in 
a room provided by the hospital [119]. Self-measurement is also free from observer 
bias and digit preference and enables patients to be more actively involved in their 
treatment, thereby improving adherence to treatment [120, 121]. 
Home measurement might also be cost-effective when compared with clinic BP 
measurement. A study of 430 patients randomized to either usual care or home 
monitoring in a closed model health maintenance organization found that the costs 
of care were 29% lower in the self-monitoring group, and BP was equally well 
controlled in both groups at the end of one year [122]. A mathematical model based 
on the Japanese Ohasama study also proposed that the introduction of home BP 
measurement for the diagnosis and treatment of hypertension would effectively 
reduce costs [123].  
So far, only two randomized, controlled trials have compared the use of home and 
clinic BP measurement for the adjustment of antihypertensive treatment. Both 
studies concluded that self-measurement leads to lower costs, less medication use 
than clinic BP measurement, and slightly poorer BP control, although with no 
differences in end-organ damage [124, 125]. From these results, one may be inclined 
to conclude that it is better to base antihypertensive treatment on clinic BP instead of 
on home BP measurement. However, both of these studies used the same target BP 
for clinic and home BP groups, although clinic BP is nearly always higher than 
home BP and 5 mmHg lower BP targets should be used for home measurement 
according to current guidelines [30, 59]. This limitation, also acknowledged by 
Verberk et al. in their article, in these studies unsurprisingly leads to more intensive 
drug therapy and greater BP decreases in the clinic BP group and somewhat nullifies 
the results of these studies [125]. 
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2.5 Association with end-organ damage and prognostic 
significance 
Already in 1977, it was reported that the changes in electrocardiographic evidence of 
left ventricular hypertrophy (ECG-LVH) were related to the degree of BP control 
and correlated better with home BP than with clinic BP [126]. After this a few small 
studies with selected hypertensive patients have concluded that clinic BP shows very 
poor or no correlation at all with hypertension-induced end-organ damage whereas 
home BP correlates significantly with echocardiographic left ventricular mass, 
PWV, and albumin excretion rate [127-130]. No association was found between 
home BP and PWV or carotid IMT in two of these studies so the results are still 
slightly mixed, although the small selected study cohorts and ongoing 
antihypertensive treatment work as confounding factors [128, 129]. On the other 
hand, one study with 239 treated hypertensive patients also concluded that very 
meticulously controlled clinic BP measured by a nurse could be as reliable as home 
BP in predicting end-organ damage [131]. In any case, data on the association 
between end-organ damage and home BP from population-based studies remain 
very scarce as only two studies, one examining carotid IMT and the other 
echocardiographic left ventricular mass, have concluded that home BP could predict 
end-organ damage better than clinic BP [78, 112]. 
Until recently, no prognostic data have been available for home BP as a risk factor 
of cardiovascular morbidity and mortality. The results from two large population 
studies have recently been published, the community-based Ohasama and Pressioni 
Arteriose Monitorate E Loro Associazioni (PAMELA) studies [52, 53, 60]. Results 
from the Ohasama study show that home BP has a stronger predictive power for 
strokes than clinic BP, and both studies have concluded that home BP is more 
closely associated with future cardiovascular mortality than clinic BP, even when 
only a few home measurements are used [52, 53, 60]. Elevated home BP also 
predicted cardiovascular events better than elevated clinic BP in a study with 4939 
elderly treated hypertensives. [87]. One smaller population study with only 662 
subjects and an 8-year follow-up did not find any prognostic superiority of home BP 
compared to clinic BP [132]. Morning home BP and evening home BP seem to 
provide equally useful information for stroke risk [133]. 
2.6 Limitations of home blood pressure measurement 
Home BP measurement also has its disadvantages. The accuracy of some home 
monitors is inadequate, especially with wrist and finger monitors [29, 30]. Reporting 
bias is possible as patients tend to under-report measurements if the patient reports 
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the BP readings him/herself [134]. BP measurements can easily be performed 
incorrectly. One study concluded that most patients with home monitors had never 
been informed by anyone of proper BP measurement techniques and that only about 
half of them knew how to place the cuff correctly, which led to poor measurement 
accuracy [135]. However, these shortcomings can often be avoided by following the 
current recommendations for home BP measurement [14, 42]. The clinical use of 
home measurement should require the use of validated and calibrated home 
monitors and good patient training. Some guidelines also recommend using a home 
monitor with a printed or electronic report of the measurements, although this does 
not completely eliminate the possibility of reporting bias [42]. 
Home BP monitors use the oscillometric technique, which may yield results that 
differ substantially from BP readings taken with a sphygmomanometer. This is 
particularly true in elderly subjects and diabetics [136, 137]. BP measuring devices 
also vary greatly in their ability to measure BP accurately in patients with 
arrhythmias, indicating that that devices should be validated independently in 
patients with arrhythmias [138]. Home BP also cannot be measured at night, which 
is possible with ambulatory BP measurement, although home BP devices with the 
capacity to perform measurements at predetermined times are coming to the market 
[139]. Some patient selection for home BP measurement may also be necessary 
because of its complexity as it still requires some instruction before the patients 
understand the procedure correctly. Furthermore, home BP measurement may 
induce anxiety in some patients, who might take an obsessional interest in BP. 
2.7 Indications for home blood pressure measurement 
Although home BP is starting to be used in almost every aspect of BP measurement 
from screening to follow-up, there are still some areas where it is particularly useful. 
Home BP measurement eliminates the white-coat effect and allows the detection of 
ICH. Home BP may also be used in virtually any patient in whom there is a 
suspicion that the clinic readings may be unrepresentative of the patients true BP. 
Home BP measurement should also be considered as a first option for a patient with 
resistant hypertension, further reducing the need for ambulatory monitoring, which 
cannot be performed in primary care and which is inconvenient for the patient. 
Home BP measurement can also be used for improving adherence to treatment in 
patients with poor compliance [120, 121]. In clinical drug trials, the duration of 
action of an antihypertensive drug can be assessed by measuring BP a number of 
times each day over several weeks [58]. 
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2.8 Summary 
It can be concluded that home BP measurement offers clear advantages not only 
over conventional clinic BP measurement, but also over ambulatory monitoring 
(Table 2). Home BP measurement allows the identification of ICH patients with 
readings under standardized conditions, little measurement variability and good 
reproducibility [63]. Home monitoring is a method preferred by patients that can 
lead to better BP control by increasing awareness of hypertension and compliance 
with drug treatment [119-121]. Preliminary data, although mostly from small, 
selected hypertensive populations, show that home BP correlates better than clinic 
BP with target-organ damage [78, 112, 126-130]. Early data of the prognostic 
superiority of home BP, when compared with clinic BP, also exist [52, 53, 60]. 
There are, however, some shortcomings to home BP measurement, which can 
mostly be avoided with good patient training and by using only validated and 
calibrated home monitors. The worst birth pains of home BP measurement are over, 
but several aspects require further elucidation. 
 
Table 2. Features of different methods of blood pressure measurement. 
Feature Clinic BP Ambulatory BP Home BP 
Outcome prediction [52, 53, 60] Poor Good Good 
Evaluation of treatment Yes Limited Yes 
Preferred by patients [119] No No Yes 
Improves adherence [120, 121] No No Yes 
Diurnal rhythm assessment [139] No Yes Yes/No 
Cost Moderate Costly Inexpensive 
Measurement bias [134] Yes No Yes/No 
Measurement frequency Low High Moderate 
Reproducibility [63] Poor Good Good 
White-coat effect Yes No No 
Estimation of paroxysmal 
hypertension No Yes No 
BP, blood pressure.    
 
So far only two studies with major limitations have compared antihypertensive 
treatment based on home measurement instead of clinic measurement [124, 125]. 
However, no studies have directly compared ambulatory BP monitoring, considered 
by many as the gold standard of BP measurement, and home BP measurement in the 
management of hypertensive patients. 
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Nearly all studies that have examined the different aspects of home BP measurement 
(i.e. agreement in diagnosis, prevalence and determinants of ICH, association with 
end-organ damage) have been performed with small cohorts of selected hypertensive 
patients in specialized hypertension clinics or academic settings. Until now, no 
nationwide studies assessing these issues have been published. Only two larger 
population-based studies exist, the PAMELA study with approximately 2000 
participants, and the Ohasama study with approximately 1800 participants [52, 60]. 
However, both are based on only one single community, the PAMELA study in the 
city of Monza, Italy and the Ohasama study in the rural town of Ohasama, Japan. 
The characteristics and lifestyle of the Japanese Ohasama population differ from 
European or North American populations. The results of the Ohasama study can not 
therefore be generalized to Caucasian populations. Furthermore, only two home 
measurements were performed by the participants of the PAMELA population and 
both the Ohasama and the PAMELA studies have published limited data on the 
association between home BP and end-organ damage [78, 112]. In addition, very 
little attention has been focused on the possible psychological determinants of ICH, 
although ICH is partly considered to be a consequence of a psychological anxiety 
reaction associated with the presence of a doctor or a nurse. 
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3 AIMS OF THE STUDY 
This thesis was set out to provide physicians with evidence that home BP 
measurement can be used effectively in clinical practice, and that it is superior to 
conventional clinic measurement. The specific goals are: 
1. To compare agreement between clinic and self-measured home BP 
measurement in a representative sample of the Finnish adult population (I). 
2. To study the prevalence and determinants of ICH in this population (II). 
3. To assess in this population whether home-measured BP is more strongly 
associated with end-organ damage than is clinic BP (III-V). 
4. To examine the independent roles of clinic BP, home BP and other risk 
factors in end-organ damage (III-V). 
5. To propose a schedule for home BP measurement based on our findings (I, 
III-V) 
6. To compare home and ambulatory BP in the adjustment of antihypertensive 
treatment in hypertensive patients (VI). 
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4 MATERIALS AND METHODS 
4.1 Studies I-V 
4.1.1 Study populations 
The study sample for the Finnish home BP monitoring study (Finn-HOME study) 
was drawn from the participants of a multidisciplinary epidemiological survey, the 
Health 2000 study, which was carried out in Finland from the fall of 2000 to the 
spring of 2001. Stratification and sampling were conducted as follows: the strata 
were the five university hospital districts, each serving approximately one million 
inhabitants and differing in several features related to geography, economic 
structure, health services and the socio-demographic characteristics of the 
population. First, the 15 largest cities were included with the probability of one. 
Next, within each of the five districts, all 65 other areas were sampled applying the 
PPS-method (probability proportional to population size). Finally, from each of 
these 80 areas, a random sample of individuals was drawn from the national 
population register. A total of 8028 persons aged 30 years or older were sampled 
from these clusters. Full details of the sampling procedure and non-responsives have 
been published elsewhere [140]. 
Of the subjects aged 45–74 years (n = 4 388), 84% (n = 3 672) agreed to participate 
in the interview and attended the health examination (Figure 2). Out of these 
subjects, 2 120 participated in the home BP measurement sub-study (Finn-HOME 
study) for persons aged 45–74 years. Home measurement of BP was not performed 
on all subjects willing to participate due to the limited number of home monitors 
(approximately 1 000). Thus, study subjects willing to participate the home BP 
measurement sub-study were practically randomly selected on the basis of monitor 
availability. These 2 120 subjects formed the basic study cohort for studies I-V. 
The study protocol of the Health 2000 survey was approved by the Epidemiology 
Ethics Committee of the Helsinki and Uusimaa hospital region, and all participants 
gave signed informed consent. 
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Figure 2. A flow chart illustrating the evolution of study samples in studies I-V. CVD, cardiovascular disease; PWV, pulse wave 
velocity.
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Figure 3. Map of Finland. Study locations of the Health 2000 survey marked in grey. 
S t u d y  I  
Subjects of the Finn-HOME cohort who had missing laboratory or health 
examination data (n = 17) or had not performed ≥ 14 valid home measurements of 
BP (n = 56) were excluded from the study. After removing subjects with one or 
more exclusion factors, the study population consisted of 2 051 subjects of 45–74 
years of age (Figure 2).  
Subjects included in the study population differed slightly from the same-aged 
subjects of the Health 2000 study, who were not included in the home-measurement 
substudy, by having a lower BMI, a lower clinic systolic BP and by smoking less 
(Study I, Table 1). 
 35 
S t u d y  I I   
Subjects of the Finn-HOME cohort who were using antihypertensive medication (n 
= 481) were excluded from the study to avoid the confounding effect of a decrease 
in BP, and the possible reclassification of patients. Subjects who had missing 
laboratory or health examination data (n = 53), had not performed ≥ 14 valid home 
measurements of BP (n = 69) or had failed to return or complete the self-report 
psychometric questionnaires (n = 224) were also excluded from the study. After 
removing subjects with one or more exclusion factors, the final study population 
consisted of 1 440 subjects, 45–74 years of age (Figure 2).  
The study population differed slightly from the respective non-participants of the 
home measurement substudy by being younger and smoking less, and by having a 
lower BMI, a lower clinic systolic BP, and a higher education level (Study II, Table 
1). 
S t u d y  I I I  
1 867 45–74 year-old subjects who participated in the Health 2000 survey were 
invited to participate in a cardiovascular disease substudy, which included 
measurement of carotid IMT. 1 526 (82%) agreed to participate. In the present 
study, analyses were restricted to those 45–74 year-old subjects of the Health 2000 
survey who had participated in both the home BP monitoring and carotid ultrasound 
substudies (n = 801). Subjects who had not completed the health examination or the 
interview properly (n = 1), had missing carotid ultrasound data (n = 21), had not 
performed ≥ 14 valid home measurements of BP (n = 19), or had incomplete 
laboratory values (n = 2) were excluded from the study. After removing subjects 
with one or more exclusion factors, the study population consisted of 758 subjects of 
45–74 years of age (Figure 2).  
Subjects included in the study population differed very slightly from the same aged 
subjects of the Health 2000 Study, who did not participate in the home measurement 
and carotid IMT substudies by having a lower BMI, a lower clinic systolic BP, a 
lower serum triglyceride level and a higher serum high density lipoprotein (HDL) 
level (Study III, Table 1). 
S t u d y  I V  
Subjects of the Finn-HOME cohort who had not performed ≥ 14 valid home 
measurements of BP (n = 56), had missing clinic BP values (n = 16), 
electrocardiograph (ECG) measurements (n = 34), or intraventricular conduction 
abnormalities (n = 47) were excluded from the study. After removing subjects with 
one or more exclusion factors, the final study population consisted of 1 989 subjects 
of 45–74 years of age (Figure 2).  
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Characteristicts of the study population were very similar to the Finnish 45–74-year-
old general population (Study I, Table 1). 
S t u d y  V  
Out of the total of 1 526 participants of the Health 2000 survey’s cardiovascular 
disease substudy, 455 subjects aged 45–74 were examined at the Turku and 
Tampere university hospital districts, where the measurement of PWV was also 
performed on all subjects. In study VI, analyses were restricted to those 45–74 year-
old subjects of the Health 2000 survey who had participated in both the home BP 
monitoring and PWV substudies (n = 243). Subjects who had not performed ≥ 14 
valid home measurements of BP (n = 3), or had incomplete laboratory values (n = 3) 
were excluded from the study. After removing subjects with one or more exclusion 
factors, the study population consisted of 237 subjects of 45–74 years of age (Figure 
2). 
Subjects included in the study population differed slightly from the same aged 
subjects of the Health 2000, who did not participate in the home BP measurement 
and PWV substudies by having a lower waist-to hip ratio, a lower pulse pressure, a 
higher serum HDL-cholesterol level, and by having proportionally more men (Study 
V, Table 1). 
4.1.2 Flow of the studies 
At an initial health interview at the subject’s home, basic background and socio-
demographic characteristics, information about health, illnesses and use of 
medication was gathered by centrally trained interviewers. A self-report 
questionnaire for the Beck Depression Inventory [141] and General Health 
Questionnaire [142], given to the study subjects to fill in and bring along to the 
physical examination. If a home monitor was available, the subjects were invited to 
participate in the home measurement sub-study. 2 120 subjects 45–74 years of age 
who were willing to participate received home BP monitors for measuring BP at 
home during the week following the health interview. 
A physical examination was performed on each subject 1–6 weeks after the health 
interview at a local health center by centrally trained doctors and nurses. Each 
subject’s height, weight, body circumference and clinic BP were measured. Fasting 
blood samples for serum glucose and lipids were taken. A 12-lead ECG was also 
recorded. After the physical examination, the subjects received a self-report 
questionnaires for the Whiteley Index [143] and Toronto Alexithymia Scale [144, 
145] to be filled in at home and mailed to the National Public Health Institute.  
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The cardiovascular disease substudy with IMT and PWV measurement was 
performed after the Health 2000 survey from December 2001 through August 2002. 
Full details of the methodology of the project have been published elsewhere [140]. 
4.1.3 Blood pressure measurement 
Clinic BP was measured by a nurse with a conventional, calibrated, mercury 
sphygmomanometer from the sitting individual’s right arm after a ten-minute rest. 
The last five minutes of rest were spent in the measuring room with the cuff around 
the right upper arm. BP was measured using a pressure cuff of appropriate size and 
methods that were in accordance to current guidelines [146]. Systolic BP and 
diastolic BP were defined according to Korotkoff sounds I and V. Means of two 
measurements performed at a two-minute interval were used to determine clinic BP. 
Home BP was self-measured with a validated, semi-automatic oscillometric device 
(Omron model HEM-722C, Omron Corp., Kyoto, Japan) according to the current 
guidelines [42, 147]. Subjects received written instructions and individual guidance 
on how to measure BP correctly. Preparations for self-measurement of BP were the 
same as for clinic BP. Seated BP was measured twice, approximately at a two-
minute interval every morning between 6 AM and 9 AM and every evening between 
6 PM and 9 PM on seven consecutive days. Home BP was determined as the mean 
of 14 duplicate measurements (28 measurements). The mean number of home BP 
measurements performed varied between 27.0 ± 2.8 and 27.1 ± 2.6 in the different 
studies. 
4.1.4 Laboratory analyses 
Venous blood samples were drawn from the antecubital vein after an overnight fast. 
HDL-cholesterol, low density lipoprotein (LDL)-cholesterol, total cholesterol, 
triglyceride, and glucose concentrations were determined enzymatically (Roche 
Diagnostics, Mannheim, Germany, for HDL- and LDL-cholesterol; Olympus 
System Reagent, Hamburg, Germany, for total cholesterol, triglyceride, and glucose) 
with a clinical chemistry analyzer (Olympus, AU400, Hamburg, Germany). 
4.1.5 Psychometric tests (II) 
Depressive symptoms and other psychopathological items were evaluated using 
several self-report questionnaires, which included: the seven-item Whiteley index 
rated on a five-point Likert scale (Whiteley-7, range 7–35) [143], which measures 
worrying and convictions about illness and somatoform disorders; a minimally 
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modified version of the 21-item Beck Depression Inventory (BDI, range 0–63) 
[141], used for assessing the existence and severity of symptoms of depression; the 
12-item General Health Questionnaire (GHQ-12, range 0–12) [142], used to detect 
the presence of non-psychotic psychiatric morbidity, especially depression and 
anxiety; and the 20-item Toronto Alexithymia Scale (TAS-20, range 20–100) for 
measuring alexithymia [144, 145]. A higher score in all previous psychometric tests 
indicates a greater risk of psychological disease. When no more than one item was 
missing from the BDI (n = 70), Whiteley-7 (n = 51), GHQ-12 (n = 28) or TAS-20 (n 
= 66), missing or incomplete data were imputed with the average score of the 
completed items and rounded to the nearest whole number. 
4.1.6 Carotid intima-media measurement (III) 
High-resolution B-mode carotid ultrasound examination of the right carotid artery 
was performed according to a standardized protocol using a 7.5 MHz linear array 
transducer. The examinations were performed by centrally trained and certified 
sonographers at five study locations. IMT measurements were performed off-line 
with the use of automated imaging processing software. One reader was responsible 
for reading all ultrasound images. 
The distal 1 cm of the common carotid artery using the beginning of the carotid 
artery bulb (the site where the two parallel walls of the common carotid artery 
diverge) as an anatomical landmark was examined first. The transducer was 
positioned to visualize both the far wall and near wall lumen-intima and media-
adventitia interfaces at a single (lateral) angle. A cine loop was recorded for 4–5 
seconds and stored on super-VHS tape. Then the sonographer focused on the carotid 
artery bulb whose distal boundary was the flow divider and proximal boundary the 
site where the two parallel walls of the common carotid artery diverge. The 
transducer was positioned to visualize the far wall. A cine loop was recorded for 4–5 
seconds of three interrogation angles (lateral, anterior, and posterior) and stored on a 
super VHS tape. 
The computer program PROSOUND (Prosound, California, USA) was used for the 
first 500 ultrasound examinations and its Windows version PROWIN 23.1 for the 
remaining 1 000 examinations to track the far wall lumen-intima and media-
adventitia echoes to determine IMT over the distal 1 cm segment of the common 
carotid artery and the carotid bulb [148, 149]. The IMT was measured from three 
digitized end-diastole images of the common carotid artery (lateral angle) and the 
carotid bulb (three interrogation angles). Three summary measures were calculated: 
1) the mean of the three average IMT measurements of the common carotid artery, 
2) the mean of the three average IMT measurements of the carotid bulb, and 3) the 
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mean of these two means (mean IMT). The mean IMT was used for all analyses in 
this study. 
The ultrasound examinations measured using the PROSOUND software were 
randomly distributed across the five study centers and glucose tolerance categories. 
To assess comparability of IMT measurements done by the two versions of the 
software, 363 randomly selected images of 60 study subjects measured by the 
PROSOUND software were measured again by the same reader using the PROWIN 
23.1 software. The mean difference of the IMT measured using the two versions of 
the software was 0.025±0.237 mm and the intra-class correlation of the two 
measurements was moderate (r = 0.780, p < 0.001) and coefficient of variation was 
17.4%. The intra-reader reproducibility of the IMT measurements using the 
PROWIN 23.1 software was also assessed. The reader measured the IMT twice from 
571 randomly selected images of 95 study subjects several weeks apart. The mean 
difference of the two measurements was 0.001±0.123 mm and the intra-class 
correlation was high (r = 0.934 (p < 0.001) and coefficient of variation was 9.2%. 
4.1.7 Pulse wave velocity measurement (IV) 
PWV measurements have been usually carried out with Doppler ultrasound or 
mechanoelectrical pulse transducers. PWV can also be measured by whole-body 
impedance cardiography, which produces a useful and reliable tool for evaluating 
arterial stiffness. In this study, the whole-body impedance cardiography 
measurements were carried out by a commercially available circulation monitor 
device CircMon B202 (JR Medical Ltd, Tallinn, Estonia). The CircMon software 
estimates the point of the whole-body impedance cardiogram that coincides with 
pulse transmission in the aortic arch. The distal impedance plethysmogram was 
recorded from a popliteal artery at the level of the knee joint. When the pulse 
pressure wave enters the aortic arch and the diameter of the aorta changes, the 
whole-body impedance decreases, and this can be measured by the voltage-sensing 
electrodes on the distal parts of the extremities. The CircMon software measures the 
time difference between the onset of the decrease in impedance in the whole-body 
impedance signal and, later, the popliteal artery signal. By means of this time 
difference and the estimated distance between the electrodes, the software calculates 
the PWV value. The impedance cardiography method has been described in detail 
previously [150].  Previous results have shown that PWV values calculated using the 
whole-body impedance cardiogram have an excellent correlation with the Doppler 
method (r = 0.91, p < 0.0001), but systematically slightly overestimate those made 
by the Doppler method. The reproducibility values of the PWV measurement are 
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similar for whole-body impedance cardiography and Doppler ultrasound (2.17 and 
2.42 m/s, respectively) [151]. 
4.1.8 Electrocardiography (V) 
Standard resting 12-lead ECGs were digitally recorded with a Marquette MAC 5000 
device and stored as digital data on a Marquette MUSE CV 5B system (Marquette 
Hellige, Milwaukee, WI, USA). All ECGs were overread, and the computerized 
diagnoses and measurements corrected if needed, by a single physician experienced 
with electrocardiography before being stored into the database. QRS duration was 
measured to the nearest 4 ms and the QRS amplitudes to the nearest 0.5 mm. ECG-
LVH was assessed with three commonly used ECG criteria: 1) the Sokolow-Lyon 
voltage (SV1 + RV5/6) [152], 2) the Cornell voltage (RaVL + SV3, plus 6 mm for 
women) [153, 154], and 3) the Cornell product (Cornell voltage x QRS duration) 
[155] as indicators of ECG-LVH. Threshold values of 35 mm, 26 mm and 2440 mm 
x ms were used to identify LVH using the Sokolow-Lyon, Cornell voltage and 
Cornell product criteria, respectively. 
4.1.9 Definitions 
Clinic hypertension was defined as a clinic BP ≥ 140/90 mmHg. Home hypertension 
was defined as a clinic BP ≥ 135/85 mmHg [42]. Subjects were identified as 
exhibiting ICH if their clinic BP was ≥ 140/90 mmHg and home BP was < 135/90 
mmHg [29]. Diabetes mellitus was defined as a fasting serum glucose level of 7.0 
mmol/l or greater or a history of the use of oral hypoglycemic agents or insulin 
injections. Antihypertensive therapy was defined as a current use of antihypertensive 
medication. Smoking was defined as a daily use of tobacco products. 
4.1.10 Statistical analyses 
Database management and statistical analysis were performed with the statistical 
software SAS, version 9.1 (SAS Institute, Cary, NC, USA). Data are reported as 
mean ± standard deviation. P-value < 0.05 was considered significant in studies III-
VI and a p-value < 0.01 in study II. 
S t u d y  I  
Continuous variables were compared using the Student’s t-test for dual comparison 
and the Tukey correction for multiple comparisons. Categorical variables were 
evaluated with the chi-square test (baseline characteristics), kappa coefficient 
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(agreement in diagnosing hypertension) or the McNemar’s test (achievement of BP 
thresholds). The mean and standard deviation of the difference between the home 
and clinic BP measurement were not constant, and adjusted difference against mean 
scatter-plots, as recommended by Bland-Altman, were used to assess the agreement 
between the two methods [23, 24]. 
S t u d y  I I  
Population weighting was used to correct the prevalence of ICH of the sample to 
correspond to that of the general Finnish population. One-way ANOVA and post-
hoc comparisons (Tukey test) were used to compare the clinically normotensive 
group, the group ICH and the group with sustained hypertension. Multivariate 
logistic regression with backward selection was used to identify the clinical, 
demographic and psychological determinants that were independently associated 
with ICH. The independent variables included in the model were those considered 
epidemiologically relevant, (i.e. gender, BMI, age, smoking status and level of 
education) as well as those that reached statistical significance in univariate analysis 
(i.e. clinic systolic and diastolic BP and heart rate, BDI score and TAS-20 score). 
Only significant variables (p < 0.05) were retained in the model. 
S t u d i e s  I I I - V  
The difference between home BP and clinic BP was compared by the paired t-test. 
Means of continuous variables were compared using a two-sample t-test. Pearson’s 
correlation was used to describe the association between continuous variables. 
Multivariate linear regression with all the variables from the univariate analysis 
included as independent variables was used to identify the determinants that were 
independently associated with increased carotid IMT or PWV. Testing equality of 
two correlations was carried out in a LISREL model (LISREL, version 8.54, SSI 
Inc., Chicago, IL, USA) by using the chi-square difference test for correlation 
matrices with and without the equality constraint [156]. 
4.2 Study VI 
4.2.1 Study population 
The study cohort consisted of previously treated or untreated patients 40–80 years of 
age, with an off-treatment daytime ambulatory diastolic BP between 86 and 110 
mmHg. Subjects were excluded if they had one or more of the following findings: 
secondary hypertension, childbearing potential, a stroke or myocardial infarction 
within 12 months prior to randomization, decompensated congestive heart failure, 
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other serious concomitant diseases which might affect survival, other indication than 
hypertension for drugs used in the trial, hypersensitivity to drugs used in the trial, 
heart rate < 50/min, insulin-treated diabetes mellitus, hepatic or renal insufficiency, 
atrial fibrillation or BMI > 35 kg/m2. 
110 patients met the inclusion criteria and underwent randomization, 56 in the home 
BP group and 54 in the ambulatory BP group (Figure 4). In the home BP group 52 
patients (92.9%) completed the study successfully, as did 46 patients (85.2%) in the 
ambulatory BP group. The baseline characteristics of the patients in the ambulatory 
BP group and home BP group were similar (I, Table 1). Most patients had taken 
antihypertensive medication. No serious adverse events were reported during the 
study. 
 
 
Figure 4. Flow of study participants. BP, blood pressure. 
4.2.2 Flow of the study 
The study was a blinded, randomized, controlled clinical trial which took place 
between April 1999 and November 2003 in the outpatient clinic of Turku University 
Hospital. The protocol for the study was approved by the Ethics Committee of the 
University of Turku, Finland. The study was conducted according to the Declaration 
of Helsinki and written informed consent was obtained from all patients. 
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At an initial pre-entry screening, a medical history for all patients was obtained and 
a standard physical examination was performed. Any previous antihypertensive 
medication was discontinued and the patients underwent a four-week placebo 
washout period. During the last week of the pre-entry period the patients measured 
their BP daily using a home monitor to obtain a baseline BP estimate. At the end of 
the four-week wash-out period a 24-hour ambulatory BP measurement was 
performed on all patients. 
Patients who met the inclusion criteria and who had no identifiable cause for 
exclusion were included in the study and were randomly allocated by random 
number generator to be treated either according to their home or ambulatory BP. 
After randomization, follow-up visits were scheduled at 6, 12, 18 and 24 weeks. All 
patients measured their home BP during the week preceding the follow-up visit. 
Ambulatory BP monitoring was also performed on all patients one day before the 
follow-up visit. The treating physician was blinded to randomization and received 
only the BP values for the method of measurement to which the patient was 
randomized, but was not told which method was used to obtain the BP values. All 
patients were treated by a single physician. The target pressure in the study for both 
the home- and ambulatory-based BP measurement groups was a diastolic BP ≤ 80 
mmHg. To achieve this goal, a standardized stepped-care antihypertensive drug 
regimen was implemented. After randomization, all patients began therapy with 
candesartan, 8 mg/d (step 1). At later visits, if the mean diastolic pressure guiding 
treatment was above the target pressure (> 80 mmHg), the treatment was intensified 
stepwise to candesartan 16 mg/d (step 2), candesartan 16 mg/d + hydroclorothiazide 
12.5 mg/d (step 3) and candesartan 16 mg/d + hydroclorothiazide 12.5 mg/d + 
felodipine 5 mg/d (step 4). Previous treatment was continued if BP was below target 
pressure, or was reduced if the patient had symptoms of hypotension. 
4.2.3 Blood pressure measurement 
Before the pre-entry screening period, all patients received individual guidance on 
how to measure BP correctly. Home BP was measured according to the current 
guidelines using a semi-automatic, oscillometric, validated Omron M4, model 
HEM-722C (Omron Corp., Kyoto, Japan) home monitor [42, 147]. After 5 minutes 
of rest in the sitting position, patients performed two consecutive self-measurements 
of BP twice daily, in the morning between 6 and 10 AM at trough and in the evening 
between 6 and 10 PM. The BP values and the time of day were self-recorded. The 
self-measured BP was the average of all 28 readings collected during seven 
consecutive days preceding each follow-up visit. 
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The 24-hour ambulatory BP monitoring was performed at 0, 6, 12, 18 and 24 weeks 
on all patients using a validated oscillometric SpaceLabs Medical 90207 (Spacelabs 
Inc., Redmond, WA, USA) ambulatory BP monitor [157]. Measurements were 
performed at 15–minute intervals during the day (6 AM to 11 PM) and at 30–minute 
intervals at night (11 PM to 6 AM). All patients received verbal and written 
instructions about the operation and care of the BP monitor. All recipients 
completed a sleep and activity diary during the ambulatory BP monitoring and night 
times were defined as full hours of self-reported actual patient sleep times. 
In addition, clinic BP measurement was performed at 0, 6, 12, 18 and 24 weeks on 
all patients. The values from these measurements were not used in guiding 
antihypertensive treatment and were not disclosed to the doctor. Systolic and 
diastolic clinic BP (Korotkoff sounds, phase V) was the mean of three consecutive 
BP measurements taken at two-minute intervals after the patients had been seated 
for five minutes by a nurse using a calibrated conventional sphygmomanometer. 
4.2.4 Statistical analyses 
With a type I error of 5% (“false positive”) and a type II error of 20% (“false 
negative”), approximately 44 patients per treatment group were needed to detect 
differences of 3 mmHg for systolic and diastolic BP, assuming a standard deviation 
of 5 mmHg for both. The number of patients withdrawing from the study was 
estimated at 10%, and therefore approximately 50 patients were enrolled per 
treatment group. 
Database analysis and management were performed with SAS statistical software, 
version 8.2 (SAS Institute Inc., Cary, NC, USA). The between-group differences in 
continuous measurements were calculated by subtracting the mean changes from 
baseline in the home BP group from those of the ambulatory BP group. The 
variables were tested for normality. The between-group comparisons for baseline 
characteristics and BP changes were performed with the two-sample Student’s t-test 
or the Mann-Whitney U-test for continuous variables, or the Chi-square test in case 
of categorical variables. The within-group comparisons for BPs were made with the 
paired Student’s t-test. A repeated-measures analysis of variance (ANOVA) was 
used to evaluate the between-group changes in BP during the study. P-values < 0.05 
were considered significant. 
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5 RESULTS 
5.1 Agreement between clinic and home blood pressure 
measurement in the Finnish population (I) 
Mean clinic BP was 137.4 ± 20.2/83.7 ± 10.7 mmHg. Mean home BP was 129.7 ± 
18.8/80.3 ± 9.4 mmHg. Mean home BP of the initial monitoring day (132.9 ± 
20.8/81.7 ± 10.4 mmHg) gave the highest and most variable (highest SD) values. 
The greatest decrease in home BP occurred between the first and second monitoring 
day. The mean difference was 2.4/1.0 mmHg (95% confidence limit 2.0–2.8, p < 
0.001 for systolic BP and 95% confidence limit 0.8–1.2, p < 0.001 for diastolic BP). 
Thereafter mean home BP remained fairly steady with a small gradual decline 
(Table 3). Among untreated subjects, the systolic and diastolic home BP were 
significantly higher in the evening than in the morning (morning: 124.9 ± 18.9/78.9 
± 9.6 mmHg, evening: 129.0 ± 18.5/79.3 ± 9.3 mmHg, p < 0.001 for both systolic 
and diastolic BP), but among subjects treated for hypertension this difference was 
non-existent for systolic BP and reversed for diastolic BP (morning: 139.2 ± 
18.3/85.1 ± 9.6 mmHg, evening: 139.7 ± 17.6/83.7 ± 9.1 mmHg, p = 0.35 for 
systolic and p < 0.001 for diastolic BP difference). The mean difference between the 
first and second measurement of each measurement occasion was 3.0/1.2 mmHg (p 
< 0.001 for systolic and diastolic BP). 
Clinic systolic BP and diastolic BP were significantly (p < 0.05) and markedly 
higher than home BP in all age groups and in the study population as a whole 
(Figures 5 and 6). The differences against mean scatter-plots are summarized by the 
mean difference between groups, and the positive Pearson's correlations (systolic 
BP: r = 0.10, p < 0.001; diastolic BP: r = 0.16, p < 0.001, Figure 5). The home–
clinic BP difference and the 95% limits of agreement increased with higher levels of 
BP. Using the currently recommended cut-off points (140/90 mmHg for clinic BP 
and 135/85 mmHg for home BP [42]), the agreement between the methods was 
moderate (overall agreement 75.2%, [kappa] coefficient 0.50, 95% confidence limit 
0.47–0.54). Clinic BP values had a sensitivity of 78.3% and a specificity of 73.0% in 
predicting high home BP (Table 4). 
 
 
 
 
 46 
 
 
 
 
 
 
 
Figure 5. Scatter-plots of difference between systolic/diastolic clinic and home blood 
pressure (BP) against mean systolic/diastolic blood pressure. Dashed lines 
indicate 95% limit of agreement between methods; continuous line indicates 
mean difference. DBP, diastolic blood pressure; SBP, systolic blood 
pressure. 
 
Figure 6. Mean systolic and diastolic blood pressures for different age groups and 
whole population. Error bars indicate standard deviation and values indicate 
mean systolic or diastolic blood pressure (BP). White color indicates clinic 
blood pressure and gray color indicates home blood pressure. 
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Table 3. Mean blood pressures of the study subjects during seven consecutive days of home measurement. 
 Day of measurement 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
All Subjects (n = 2051)        
   Systolic 132.9 ± 20.8234567 130.5 ± 20.217 129.6 ± 19.81 129.1 ± 19.71 128.9 ± 19.51 128.5 ± 19.31 128.4 ± 19.212 
   Diastolic 81.7 ± 10.434567 80.7 ± 10.2 80.4 ± 10.01 80.0 ± 10.11 79.8 ± 10.01 79.8 ± 9.91 79.7 ± 10.01 
Treated (n = 464)        
   Systolic 143.1 ± 19.4567 140.4 ± 19.1 139.4 ± 18.5 138.9 ± 18.9 138.6 ± 18.21 137.7 ± 18.51 137.5 ± 18.01 
   Diastolic 85.9 ± 9.9 84.6 ± 9.8 84.6 ± 9.8 84.1 ± 10.0 84.0 ± 9.8 83.9 ± 9.8 83.8 ± 10.1 
Not Treated (n = 1587)        
   Systolic 130.0 ± 20.2234567 127.7 ± 19.71 126.7 ± 19.31 126.3 ± 19.01 126.0 ± 19.01 125.8 ± 18.71 125.7 ± 18.71 
   Diastolic 80.5 ± 10.234567 79.6 ± 10.0 79.1 ± 9.71 78.9 ± 9.91 78.6 ± 9.71 78.6 ± 9.61 78.5 ± 9.71 
Values reported as mean ± SD. Superscript numbers indicate a significant difference (ANOVA, p < 0.01) as compared with the mean BP of the day indicated by 
the number.      
 
 
Table 4. Agreement between methods, and the sensitivity, specificity, and likelihood ratios for a positive and negative test of 
clinic blood pressure in predicting high home blood pressure. 
    Likelihood ratio Likelihood ratio Kappa 
Measurement Agreement (%) Sensitivity (%) Specificity (%) (positive) (negative) coefficient (95% Cl) 
Systolic 75.3 74.0 76.1 3.1 0.3 0.49 (0.45–0.52) 
Diastolic 78.6 61.0 85.7 4.3 0.5 0.47 (0.43–0.51) 
Both 75.2 78.3 73.0 2.9 0.3 0.50 (0.47–0.54) 
The positive likelihood ratio indicates how much the odds of home hypertension increase when a patient is clinic hypertensive. The negative likelihood 
ratio indicates how much the odds of the home hypertension decrease when a patient is clinic normotensive. 95% Cl, 95% confidence limit. 
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To assess home BP status in the Finnish population, home BP values in subjects 
determined normotensive by clinic BP (clinic BP < 140/90 mmHg, n = 918), 
untreated hypertensive subjects (no self-reported use of antihypertensive medication 
and clinic BP ≥ 140/90 mmHg, n = 669) and treated hypertensive subjects (self-
reported use of antihypertensive medication, n = 464) were analyzed. The mean 
clinic and home BP and control rates are shown in Table 5. 
Normotensive subjects had significantly lower clinic and home BP values than 
untreated and treated hypertensive individuals. Untreated hypertensive individuals 
had higher clinic BP values than treated hypertensive individuals, but home BP 
values were similar for both groups. Among all subjects, clinic BP measurements 
(clinic BP ≥ 140/90 mmHg) slightly overestimated the prevalence of high BP as 
compared with home measurements (home BP ≥ 135/85 mmHg), 48.8% versus 
42.5%, p < 0.001. Control of hypertension assessed with home BP was non-
significantly higher among the treated hypertensive individuals than with clinic BP, 
32.8% versus 28.7%, p = 0.11. The control of hypertension tended to be higher with 
home BP than with clinic BP in women (37.6% versus 31.4%, p = 0.07), but not in 
men (26.6% versus 25.1%, p = 0.71). 
 
Table 5. Mean blood pressure values for clinic normotensive, treated hypertensive 
and untreated hypertensive subjects. 
 
Characteristic All Subjects Normotensive Treated HT Untreated HT p 
n 2051 918 464 669  
Male, n 952 (46.4%) 395 (43.0%) 203 (43.8%) 354 (52.9%)  
Age, years 56.4 ± 8.5 53.7 ± 7.6 60.1 ± 8.1 57.4 ± 8.8 < 0.01 
Clinic Systolic BP, mmHg 137.4 ± 20.2 122.0 ± 10.7 146.7 ± 18.9 * 152.2 ± 15.5 *† < 0.01 
Clinic Diastolic BP, mmHg 83.7 ± 10.7 77.3 ± 7.3 86.5 ± 10.7 * 90.6 ± 9.3 *† < 0.01 
Home Systolic BP, mmHg 129.7 ± 18.8 117.7 ± 13.4 139.4 ± 17.3 * 139.5 ± 16.5 * < 0.01 
Home Diastolic BP, mmHg 80.3 ± 9.4 74.9 ± 7.2 84.4 ± 8.9 * 84.8 ± 8.5 * < 0.01 
Clinic BP < 140/90 mmHg, n 1050 (51.2%) 918 (100%) 133 (28.7%) 0 (0%)  
Home BP < 135/85 mmHg, n 1180 (57.5%) 788 (85.8%) 152 (32.8%) 240 (35.9%)  
Values reported as mean ± SD.  † indicates p < 0.05 versus treated HT, * indicates p < 0.05 versus normotensive. 
BP, Blood Pressure; HT, hypertensive; p, p-value for analysis of covariance between the 3 groups. 
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5.2 Prevalence and determinants of isolated clinic hypertension in 
the Finnish population (II) 
The prevalence of ICH in the study population was 15.4%. After population 
weighting, the prevalence of ICH in the Finnish population of 45–74 year olds was 
15.6%, insignificantly higher in men than in women (17.0% versus 14.3%, p = 
0.18). Among untreated clinic hypertensive individuals, the weighted prevalence of 
ICH was 37.5%. The comparisons between the normotensive group, the ICH group 
and the sustained hypertensive group for the demographic, psychological and 
clinical characteristics are reported in Table 6.  
The age and sex distribution and educational level of subjects with ICH was 
between those of the sustained hypertensive and normotensive individuals (Table 6). 
There were non-significantly fewer smokers among the subjects with ICH than 
among the normotensive (p = 0.07) or sustained hypertensive individuals (p = 0.25). 
Clinic and home BP levels of the subjects with ICH were between those of the 
sustained hypertensive and normotensive individuals (Table 6). However, the 
systolic and diastolic white-coat effect (clinic minus home BP) was significantly 
higher (p < 0.001) in the ICH group than in the two other groups. The reduction in 
BP between the first and second clinic BP measurements was similar for all groups. 
Sustained hypertensive individuals had higher clinic and home heart rates than 
subjects with ICH and normotensive individuals. The ICH group had higher clinic (p 
= 0.02) but similar home heart rates compared with normotensive individuals (p = 
0.99). 
There was no significant difference in the BMI between the subjects with ICH and 
normotensive individuals (p = 0.43), but the sustained hypertensive individuals were 
more obese than subjects in the other groups (p < 0.001). There were no significant 
differences between the subjects with ICH and sustained hypertensive individuals in 
diabetes prevalence, serum glucose or serum lipid levels. The ICH group had higher 
levels of serum glucose (p = 0.009), total cholesterol (p = 0.002) and triglycerides (p 
= 0.006) than the normotensive group. The difference in glucose levels became non-
significant after adjusting for age and sex. 
In the psychometric tests, there were no between-group differences in the GHQ-12 
and Whiteley-7 scores. Sustained hypertensive individuals had significantly higher 
scores in the BDI and TAS-20 than the two other groups. After adjusting for age and 
sex, the difference in the TAS-20 score between the sustained hypertensive and 
normotensive individuals became non-significant. 
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Table 6. Characteristics of subjects grouped by hypertension status. 
Characteristic 1. ST (n=371) 2. ICH (n=222) 3. NT (n=847) Overall (p) 1 vs. 2 (p) 1 vs. 3 (p) 2 vs. 3 (p) 
Age, y 57.9 ± 8.6 55.8 ± 8.3 53.5 ± 7.6 < 0.001 0.006 < 0.001 < 0.001 
Men, % 54.5 51.4 42.5 < 0.001 0.74 < 0.001 0.0048 
Smokers, % 20.8 15.3 22.1 0.09 0.25 0.86 0.07 
Upper level education, % 19.4 21.6 30.8 < 0.001 0.82 < 0.001 0.02* 
Medium level education, % 28.6 32.4 32.6 0.36 0.59 0.35 0.99 
Lower level education, % 52.0 46.0 36.6 < 0.001 0.31 < 0.001 0.03* 
BMI, kg/m2 28.8 ± 4.1 26.4 ± 4.0 26.0 ± 3.8 < 0.001 < 0.001 < 0.001 0.43 
Waist-to-hip ratio 0.94 ± 0.08 0.91 ± 0.09 0.90 ± 0.08 < 0.001 < 0.001 < 0.001 0.02* 
Diabetes, % 6.5 4.5 2.5 0.003 0.45 0.002* 0.34 
Serum glucose, mmol/l 5.6 ± 1.0 5.6 ± 1.1 5.4 ± 0.7 < 0.001 0.53 < 0.001 0.009* 
Serum total cholesterol, mmol/l 6.4 ± 1.2 6.3 ± 1.2 6.0 ± 1.0 < 0.001 0.30 < 0.001 0.002 
Serum HDL-cholesterol, mmol/l 1.3 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 < 0.001 0.08 < 0.001 0.66 
Serum LDL-cholesterol, mmol/l 4.2 ± 1.3 4.1 ± 1.2 3.9 ± 1.1 < 0.001 0.44 < 0.001 0.17 
Serum triglycerides, mmol/l 1.7 ± 1.1 1.6 ± 1.1 1.4 ± 0.8 < 0.001 0.49 < 0.001 0.006 
Clinic systolic BP, mmHg 155.2 ± 16.3 146.0 ± 10.2 121.9 ± 10.6 < 0.001 < 0.001 < 0.001 < 0.001 
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Clinic diastolic BP, mmHg 92.3 ± 9.6 88.0 ± 7.6 77.4 ± 7.2 < 0.001 < 0.001 < 0.001 < 0.001 
Clinic heart rate, per min 69.8 ± 11.3 67.8 ± 10.5 65.7 ± 9.6 < 0.001 0.06** < 0.001 0.02 
1st-2nd systolic BP difference, mmHg 1.3 ± 5.9 2.0 ± 6.0 1.7 ± 4.9 0.20 0.21 0.33 0.75 
1st-2nd diastolic BP difference, mmHg 1.1 ± 4.0 1.2 ± 3.4 0.8 ± 4.1 0.19 0.99 0.30 0.34 
Home systolic BP, mmHg 147.5 ± 13.3 124.0 ± 7.3 117.3 ± 13.1 < 0.001 < 0.001 < 0.001 < 0.001 
Home diastolic BP, mmHg 88.8 ± 7.1 77.8 ± 4.8 74.7 ± 7.1 < 0.001 < 0.001 < 0.001 < 0.001 
Home heart rate, per min 70.3 ± 9.0 67.9 ± 9.2 67.9 ± 8.5 < 0.001 0.004 < 0.001 0.99 
Systolic white coat effect, mmHg 7.7 ± 15.1 22.1 ± 10.6 4.6 ± 11.8 < 0.001 < 0.001 < 0.001 < 0.001 
Diastolic white coat effect, mmHg 3.5 ± 8.0 10.3 ± 6.5 2.7 ± 7.2 < 0.001 < 0.001 0.19 < 0.001 
BDI, points 7.6 ± 7.0 6.1 ± 5.6 6.7 ± 6.5 0.02 0.02 0.08 0.41 
GHQ-12, points 1.8 ± 2.9 1.4 ± 2.5 1.8 ± 2.9 0.11 0.13 0.94 0.14 
Whiteley-7, points 13.6 ± 4.1 13.6 ± 3.6 13.6 ± 3.9 0.99 0.99 0.99 0.99 
TAS-20, points 48.2 ± 10.9 45.2 ± 10.8 45.1 ± 10.8 < 0.001 0.004 < 0.001* 0.99 
Values expressed as mean ± SD. * indicates nonsignificance (p > 0.05) and ** significance (p < 0.05) after adjusting for age and gender. ST, sustained  
Hypertensives; ICH, isolated clinic hypertension; NT, normotensives;  p, p-value; BMI, body mass index; BP, blood pressure; BDI, Beck Depression  
Inventory; GHQ-12, 12-item General Health Questionnaire; Whiteley-7, 7-item Whiteley Index; TAS-20, 20-Item Toronto Alexithymia Scale; 1st-2nd BP  
difference, difference between 1st and 2nd clinic blood pressure measurements. 
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Two multivariate logistic regression models were performed to identify independent 
determinants of ICH. The whole study population was analyzed in the first 
regression model. Normotensive individuals were excluded from the second 
regression model to further examine the factors that would help identify the subjects 
with ICH from the sustained hypertensive individuals. 
In the first regression model with ICH set as the dependent variable, higher clinic 
systolic and diastolic BP, lower BMI and a non-smoking status were associated with 
ICH after controlling with sex, age, clinic heart rate, educational level and scores 
from the BDI and TAS-20 (Table 7). 
 
Table 7. Multivariate-adjusted odds ratios of selected clinical variables for isolated 
clinic hypertension, whole study population included in analysis. 
Variable β Odds Ratio 95% Cl p 
BMI, kg/m2 -0.09 0.91 0.87–0.95 < 0.01 
Smoking (yes = 0, no = 1) 0.21 1.51 1.00–2.27 0.048 
Office systolic BP, mmHg 0.03 1.03 1.02–1.04 < 0.01 
Office diastolic BP, mmHg 0.03 1.04 1.02–1.05 < 0.01 
R-square = 0.22, p < 0.001. BMI, body mass index; BP, blood pressure;  TAS-20, 20-item Toronto  
Alexithymia Scale; 95% Cl, 95% confidence limit; p, p-value.  
 
In the second regression model, including only sustained hypertensive individuals 
and subjects with ICH, lower clinic systolic and diastolic BP, lower BMI, lower 
score in the TAS-20 and a non-smoking status were associated with ICH after 
controlling for sex, age, clinic heart rate, educational level and score from the BDI 
(Table 8). In this population, the prevalence of ICH was inversely proportional to 
the severity of clinic BP values (Figure 7). 
In the first regression model, including the whole study population, higher clinic BP 
was a predictor of ICH, and in the second regression model, including only clinic 
hypertensive individuals, lower clinic BP was a predictor of ICH. Therefore, ICH 
seems to be associated with mildly elevated clinic BP. 
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Table 8. Multivariate-adjusted odds ratios of selected clinical variables for isolated 
clinic hypertension, only clinic hypertensives included in analysis. 
Variable β Odds Ratio 95 % Cl p 
BMI, kg/m2 -0.15 0.86 0.82–0.91 < 0.01 
Smoking (yes = 0, no = 1) 0.33 1.92 1.17–3.16 0.01 
Office systolic BP, mmHg -0.05 0.95 0.93–0.96 < 0.01 
Office diastolic BP, mmHg -0.04 0.96 0.94–0.98 < 0.01 
TAS-20, points -0.03 0.98 0.96–0.99 0.005 
R-square = 0.09, p < 0.001. BMI, body mass index; BP, blood pressure; TAS-20, 20-item Toronto  
Alexithymia Scale; 95% Cl, 95% confidence limit; p, p-value. 
 
 
 
Figure 7. Frequency of isolated clinic hypertension (ICH) among clinic hypertensive 
individuals by quartiles of systolic and diastolic clinic blood pressure (BP). 
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5.3 Home blood pressure and end-organ damage (III-V) 
5.3.1 Carotid atherosclerosis (III) 
The associations between carotid IMT and various BP parameters are presented in 
Table 9 and Figure 8. All BP parameters correlated significantly with carotid IMT (p 
< 0.001 for all), except for clinic diastolic BP, which did not reach statistical 
significance (p = 0.07). Systolic BP and pulse pressure had a stronger correlation 
with IMT than did diastolic BP for both clinic and home measurements. The Pearson 
correlation coefficients for carotid IMT and home/clinic BP differed significantly in 
favour of the home measurement of BP (p < 0.001 for systolic BP, diastolic BP and 
pulse pressure). 
Figure 8. Scatter plots of systolic and diastolic blood pressure (BP) versus carotid 
intima-media thickness. White dots represent clinic blood pressure, and 
black dots home blood pressure. Regression lines represent the relationship 
between clinic (dashed lines) or home (solid lines) blood pressure and 
carotid intima-media thickness. 
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Table 9. Association between carotid intima–media thickness or pulse wave velocity 
and selected clinical variables. 
 Intima-media thickness (n = 758) Pulse wave velocity (n = 237) 
Continuous variable r p-value Difference r p-value Difference 
Home SBP 0.35 < 0.001 0.65 < 0.001 
Clinic SBP 0.25 < 0.001 
< 0.001 
0.50 < 0.001 
< 0.001 
Home DBP 0.20 < 0.001 0.51 < 0.001 
Clinic DBP 0.07 0.07 
< 0.001 
0.37 < 0.001 
< 0.001 
Home PP 0.37 < 0.001 0.62 < 0.001 
Clinic PP 0.28 < 0.001 
< 0.001 
0.40 < 0.001 
< 0.001 
Age 0.50 < 0.001  0.51 < 0.001  
Triglycerides 0.20 < 0.001  0.26 < 0.001  
HDL-cholesterol -0.20 < 0.001  -0.23 0.001  
LDL-cholesterol 0.13 < 0.001  0.07 0.27  
Total cholesterol 0.10 < 0.001  0.08 0.24  
Glucose 0.12 0.001  0.44 < 0.001  
WH ratio 0.21 < 0.001  0.34 < 0.001  
Body mass index 0.14 < 0.001  0.28 < 0.001  
       
Categorical variable Mean IMT, mm p-value Mean PWV, m/s p-value 
Smoking     
  Present 0.94 ± 0.26 12.7 ± 2.9 
  Absent 0.93 ± 0.23 
0.68 
12.9 ± 3.1 
0.70 
Gender     
  Male 0.97 ± 0.26 13.9 ± 2.9 
  Female 0.90 ± 0.20 
< 0.001 
12.2 ± 2.9 
< 0.001 
Diabetes     
   Present 1.08 ± 0.38 17.2 ± 2.9 
   Absent 0.92 ± 0.22 
0.007 
12.6 ± 2.6 
< 0.001 
IMT reported as mean ± SD. Difference, p-value for difference in correlations; IMT, intima-media 
thickness; r, Pearson's correlation coefficient; PP, pulse pressure; SBP, systolic blood pressure; DBP, 
diastolic blood pressure, WH, waist-to-hip, PWV, pulse wave velocity. 
 
In a univariate analysis, age, triglycerides, serum glucose, waist-to-hip ratio, BMI, 
LDL-cholesterol, and total cholesterol showed a significant positive correlation with 
carotid IMT, whereas HDL-cholesterol was negatively associated with carotid IMT 
(Table 9). In addition, men and individuals with diabetes had a significantly thicker 
carotid IMT than women and individuals without diabetes. A linear regression was 
performed to identify the determinants that are independently associated with carotid 
IMT (Table 10). With IMT set as the dependent variable, age, home systolic BP, 
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triglycerides, male sex, smoking, diabetes, and LDL-cholesterol were independently 
associated with increased IMT. These determinants explained 32% of the variance in 
carotid IMT (p < 0.001). Clinic systolic BP, HDL-cholesterol, and BMI were not 
independently associated with IMT, and did not increase the coefficient of 
determination. 
 
Table 10. Multivariate linear regression for carotid intima-media thickness (n = 758). 
Variable β SE p-value 
Intercept -0.045 - - 
Age, years 0.013 0.45 < 0.001 
Home systolic BP, mmHg 0.002 0.15 0.002 
Triglycerides, mmol/L 0.019 0.10 0.006 
Gender (male = 0, female = 1) -0.041 -0.09 0.009 
Smoking (no = 0, yes = 1) 0.045 0.07 0.017 
Diabetes (no = 0, yes = 1) 0.067 0.07 0.035 
LDL-cholesterol, mmol/l 0.014 0.06 0.041 
Clinic systolic BP, mmHg 0.000 -0.04 0.412 
HDL-cholesterol, mmol/l -0.017 -0.03 0.456 
Body mass index, kg/m2 0.000 0.01 0.882 
R-square = 0.32, p < 0.001. IMT, intima-media thickness; SE, standardized estimate;  BP, blood pressure.  
 
To investigate further how the number of home BP measurements affects the 
association between home BP and carotid IMT, the relationship between IMT and 
BP averaged over a cumulative number of days of home BP measurement was 
evaluated (Table 11). The correlation coefficients between systolic or diastolic BP 
and carotid IMT did not increase with the number of measurements. The 
associations between home BP and carotid IMT were, however, stronger compared 
with clinic BP, even with a low number of home measurements. When individual 
days of measurement and their correlation with carotid IMT were examined, there 
was no difference in the strength of the association provided by different home BP 
monitoring days. The r value of the first day was arithmetically the highest (Table 
11). 
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Table 11. Correlation between carotid intima–media thickness or pulse wave velocity 
and blood pressure. 
BP Parameter First 2 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Cumulative - IMT         
   Systolic BP - - 0.353 0.350 0.348 0.343 0.347 0.348 
   Diastolic BP - - 0.215 0.211 0.206 0.201 0.201 0.204 
Individual - IMT         
   Systolic BP 0.342 0.346 0.343 0.323 0.324 0.306 0.343 0.332 
   Diastolic BP 0.227 0.214 0.203 0.191 0.173 0.169 0.182 0.200 
Cumulative - PWV         
   Systolic BP - - 0.643 0.656 0.651 0.653 0.657 0.653 
   Diastolic BP - - 0.504 0.507 0.494 0.504 0.514 0.511 
Individual - PWV         
   Systolic BP 0.589 0.622 0.633 0.644 0.572 0.611 0.643 0.600 
   Diastolic BP 0.471 0.493 0.488 0.461 0.406 0.502 0.528 0.481 
Correlations are reported as Pearson's correlations. p < 0.001 for all correlations. BP, blood pressure; IMT,  
intima-media thickness; PWV pulse wave velocity; First 2, mean of the first two morning measurements.  
Cumulative, relationship between IMT/PWV and BP averaged over cumulative number of days of home BP  
measurements; Individual, the relationship between IMT/PWV and BP on individual days of measurement. 
5.3.2 Arterial stiffness (IV) 
The associations between PWV and various BP parameters are reported in Table 9 
and Figure 9. All BP parameters correlated significantly with PWV (p < 0.001 for 
all). Systolic BP and pulse pressure had a stronger correlation with PWV than did 
diastolic BP for both clinic and home measurements. The Pearson correlation 
coefficients for PWV and home/clinic BP differed significantly in favor of home 
measurement of BP (p < 0.001 for systolic BP, diastolic BP and pulse pressure). 
In a univariate analysis, age, triglycerides, BMI, waist-to-hip ratio, and serum 
fasting glucose showed a significant positive correlation with PWV, while HDL-
cholesterol was negatively associated with PWV (Table 9). In addition, men and 
diabetics had a significantly greater PWV than women and non-diabetics. A linear 
regression was performed to identify the determinants that are independently 
associated with PWV (Table 12). With PWV set as the dependent variable, age, 
home systolic BP, and diabetes were independently associated with increased PWV. 
These determinants explained 60% of the variance in PWV (p < 0.001). Clinic 
systolic BP, triglycerides, LDL-cholesterol, smoking, HDL-cholesterol, gender, 
waist-to-hip ratio and BMI were not independently associated with PWV, and did 
not increase the coefficient of determination. 
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Figure 9. Scatter plots of systolic and diastolic blood pressure (BP) versus pulse wave 
velocity. White dots represent clinic blood pressure, and black dots home 
blood pressure. Regression lines represent the relationship between clinic 
(dashed lines) or home (solid lines) blood pressure and pulse wave velocity. 
Table 12. Multivariate linear regression for pulse wave velocity (n = 237). 
Variable β SE p-value 
Intercept -6.29 - - 
Home systolic BP, mmHg 0.07 0.44 < 0.001 
Age, years 0.15 0.37 < 0.001 
Diabetes (no = 0, yes = 1) 2.42 0.19 < 0.001 
LDL-cholesterol, mmol/l -0.17 -0.06 0.21 
WH ratio 2.77 0.08 0.32 
Triglycerides, mmol/L 0.13 0.04 0.41 
Gender (male = 0, female = 1) -0.33 -0.05 0.42 
Smoking (no = 0, yes = 1) 0.29 0.03 0.43 
Body mass index, kg/m2 -0.02 -0.03 0.55 
Clinic systolic BP, mmHg 0.00 0.03 0.72 
HDL-cholesterol, mmol/l -0.04 0.00 0.93 
R-square = 0.60, p < 0.001. PWV, pulse wave velocity; SE, standardized estimate; BP, blood pressure.  
 
To investigate further how the number of home BP measurements affects the 
association between home BP and PWV, the relationship between PWV and BP 
averaged over a cumulative number of days of home BP measurement was evaluated 
(Table 11). The correlation coefficients increased only slightly with the number of 
measurements, especially for diastolic BP. No significant increase occurred after the 
third day. Exclusion of measurements performed during the first day of 
measurement from the mean home BP did not result in a higher correlation 
 59 
coefficient for home BP. The associations between home BP and PWV were 
stronger as compared with clinic BP, even with a low number of home 
measurements. When individual days of measurements and their correlation with 
PWV were examined, there was no significant difference in the strength of the 
association provided by different home BP monitoring days (Table 11). 
5.3.3 Left ventricular hypertrophy (V) 
The correlation coefficients for home or clinic BP and ECG-LVH are presented in 
Table 13. Both home and clinic BP were significantly associated with ECG-LVH (p 
< 0.001 for all correlations). Home BP, however, correlated significantly better with 
ECG-LVH than did clinic BP, except for the association between systolic BP and 
the Sokolow–Lyon voltage (Table 13). Even the mean of the initial two home BP 
measurements correlated equally well (systolic BP), or better (diastolic BP) with 
ECG-LVH than did clinic BP (Table 13). The Cornell voltage and Cornell product 
were more closely associated with BP than the Sokolow–Lyon voltage, especially 
for home BP. 
 
Table 13. Correlation coefficients for home or clinic blood pressure and ECG 
parameters. 
  Systolic BP Diastolic BP 
ECG Parameter  Clinic Home wk Home 2 Clinic Home wk Home 2 
Sokolow-Lyon Pearson's r 0.22 0.23 0.21 0.12 0.17 0.16 
 p-value - 0.60 0.17 - 0.009 0.05 
Cornell Voltage Pearson's r 0.25 0.30 0.28 0.12 0.21 0.20 
 p-value - 0.004 0.14 - < 0.001 < 0.001 
Cornell Product Pearson's r 0.24 0.30 0.27 0.14 0.22 0.21 
 p-value - 0.001 0.10 - < 0.001 < 0.001 
All correlations were statistically significant (p < 0.001). BP, blood pressure; p-value, p-value for the difference 
between clinic and home correlation; home wk, mean of all home BP measurements included in the analysis; 
home 2, mean of the 2 initial home measurements included in the analysis. 
 
The risk ratios of ECG-LVH were calculated to assess whether home hypertension 
(home BP ≥ 135/85 mm Hg) poses a higher risk than clinic hypertension (clinic BP 
≥ 140/90 mm Hg) [42]. Subjects on antihypertensive medication (n = 450) were 
excluded from this analysis to avoid any confounding effects. An equal share of 
home and clinic hypertensives met the criteria for ECG-LVH as reported in Table 
14. No difference was seen in the prevalence of ECG-LVH between clinic and home 
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hypertensives. The prevalence and risk of ECG-LVH were slightly, but not 
significantly higher in subjects who had elevated home and clinic BP. 
To investigate further how the number of home BP measurements affects the 
association between home BP and ECG-LVH, the relationship between the number 
of days of home BP measurement and the correlation between home BP and ECG-
LVH was evaluated (Figure 10). The correlation coefficients increased only slightly 
with the number of measurements, especially for diastolic BP. Exclusion of 
measurements performed during the first day of measurement from mean home BP 
did not result in a higher correlation coefficients, and the best possible correlation 
between systolic and diastolic BP and ECG-LVH was achieved by using the mean 
of all measurements as home BP. 
 
 
 
 
 
 
 
 
Figure 10. The relationship between the number of days of home blood pressure (BP) 
measurement and the correlation between home blood pressure and ECG-
LVH. Dashed lines indicate correlation between clinic blood pressure and 
ECG-LVH. 
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Table 14. Proportion of unmedicated subjects (n = 1539) with ECG diagnosis. 
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 Home BP (%) Clinic BP (%) Home and clinic BP (%) Risk Ratios (95% Cl) 
ECG criteria 
NT 
(n=1005) 
HT  
(n=534) 
NT  
(n=895) 
HT  
(n=644) 
NT 
(n=1127) 
HT  
(n=412) Home HT Clinic HT 
Home and 
clinic HT 
Cornell Product ≥ 2440 mm*ms 6.4 14.6 5.7 14.1 6.7 16.0 2.3 (1.7–3.1) 2.5 (1.8–3.4) 2.6 (1.9–3.7)
Cornell Voltage ≥ 26 mm 5.2 15.0 4.9 13.7 5.8 16.3 2.9 (2.1–4.0) 2.8 (2.0–3.9) 3.2 (2.2–4.6)
Sokolow-Lyon ≥ 35 mm 6.9 16.7 7.2 14.6 7.7 17.2 2.4 (1.8–3.3) 2.0 (1.5–2.8) 2.5 (1.8–3.5)
Values reported as % of subjects with ECG diagnosis of left ventricular hypertrophy. Home hypertension was defined as a home blood  pressure ≥ 135/85 mmHg, 
and clinic hypertension as a clinic blood pressure ≥ 140/90 mmHg. Risk ratios are reported as clinic or home hypertensives' risk for electrocardiographic evidence 
of left ventricular hypertrophy. BP, blood pressure; NT, normotensives; HT,  hypertensives; H, home; C, clinic. 
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5.4 Home versus ambulatory monitoring in the adjustment of 
antihypertensive therapy (VI) 
Home, ambulatory, and clinic BP decreased significantly (p < 0.001), both in the 
home and ambulatory BP groups during the 24-week follow-up. No significant 
differences between the two groups were seen in home, daytime ambulatory, or 
clinic BP curves (Figure 11). There were no significant between-group differences 
in BP changes at the end of the study (Table 15). 
 
 
 
 
 
 
 
 
 
 
Figure 11. Mean home, daytime ambulatory, and clinic blood pressures (BP) during the 
study. Error bars indicate SEs. P-values refer to comparison of curves by 
ANOVA for repeated measures. 
The pre-specified BP guiding treatment (diastolic home BP or ambulatory daytime 
BP) was 0.9 mm Hg lower in the home BP group at the end of the study (Figure 12). 
The achieved corresponding BP values were 80.5 ± 5.4 mm Hg in the home BP 
group and 81.4 ± 5.2 mm Hg in the ambulatory BP group. 
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Table 15.  Blood pressures for the two treatment groups at randomization and after a 
24-week follow-up. 
BP HBP Group (n = 52) ABP Group (n = 46) Difference, (95% Cl) p-value 
Home     
   Systolic     
      At Randomization 143.4 ± 15.1 143.7 ± 14.6 -0.3 (-6.3–5.6) 0.91 
      Change -17.1 ± 1.7 -19.7 ± 1.7 2.6 (-2.3–7.4) 0.29 
   Diastolic     
      At Randomization 90.5 ± 6.7 90.6 ± 6.3 -0.1 (-2.8–2.5) 0.91 
      Change -10.0 ± 0.8 -12.6 ± 1.1 2.6 (-0.1–5.2) 0.06 
Ambulatory: 24-h     
   Systolic     
      At Randomization 144.9 ± 12.0 143.2 ± 11.0 1.7 (-2.9–6.4) 0.46 
      Change -17.3 ± 1.2 -17.9 ± 1.3 0.6 (-3.0–4.3) 0.72 
   Diastolic     
      At Randomization 90.7 ± 7.1 91.7 ± 5.9 -1.0 (-3.6–1.7) 0.46 
      Change -10.8 ± 0.9 -12.3 ± 0.8 1.5 (-1.0–3.9) 0.23 
Ambulatory: Day     
   Systolic     
      At Randomization 148.4 ± 12.8 146.3 ± 11.0 2.1 (-2.7–6.9) 0.39 
      Change -17.9 ± 1.3 -18.6 ± 1.4 0.6 (-3.2–4.4) 0.75 
   Diastolic     
      At Randomization 93.7 ± 7.6 94.3 ± 6.0 -0.7 (-3.4–2.1) 0.63 
      Change -11.2 ± 1.0 -12.9 ± 0.8 1.7 (-0.9–4.4) 0.20 
Ambulatory: Night     
   Systolic     
      At Randomization 128.4 ± 13.1 127.5 ± 12.0 0.9 (-4.1–6.0) 0.72 
      Change -14.8 ± 1.3 -15.8 ± 1.5 1.0 (-2.9–4.9) 0.62 
   Diastolic     
      At Randomization 76.6 ± 7.9 78.8 ± 7.5 -2.2 (-5.3–0.9) 0.16 
      Change -9.8 ± 1.0 -11.2 ± 1.0 1.4 (-1.4–4.2) 0.34 
Clinic     
   Systolic     
      At Randomization 149.3 ± 17.5 149.2 ± 16.0 0.1 (-6.6–6.9) 0.97 
      Change -18.5 ± 1.8 -17.5 ± 1.6 1.1 (-3.7–5.9) 0.66 
   Diastolic     
      At Randomization 94.4 ± 9.6 96.3 ± 8.1 -2.0 (-5.6–1.6) 0.28 
      Change -10.3 ± 1.3 -11.7 ± 1.2 1.3 (-5.0–2.3) 0.46 
Values at randomization are expressed as mean ± SD. Change refers to the mean changes (SE) from  
randomization to the end of the follow-up period. All within group differences were significant (p < 0.001).  
BP, blood pressure; HBP, home blood pressure; ABM, ambulatory blood pressure; Cl., confidence limit. 
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Figure 12. Mean blood pressures 
(BP) guiding treatment 
during the study. Error 
bars indicate SEs. P-
value refers to 
comparison of curves by 
ANOVA for repeated 
measures. 
 
 
By week 24, diastolic home BP was ≤ 80 mm Hg for 30 of 52 patients (57.7%) in 
the home BP group and for 28 of 46 patients (60.9%) in the ambulatory BP group. 
Diastolic daytime ambulatory BP was ≤ 80 mm Hg for 20 of 52 patients (38.5%) in 
the home BP group and for 20 of 46 patients (43.5%) in the ambulatory BP group. 
Thus, the pre-specified target BP in the home BP group (diastolic home BP ≤ 80 mm 
Hg) was reached in 57.7% of the patients and in the ambulatory BP group (diastolic 
daytime ambulatory BP ≤ 80 mm Hg) in 43.5% of the patients. This 14.2% 
difference between groups did not reach statistical significance (95% confidence 
limit -5.4% to 33.8%, p = 0.16). 
A similar share of patients had progressed to combination drug therapy in both 
treatment groups by the end of the study (65.4% versus 67.4%, p = 0.83). Non-
significantly more patients were receiving drug therapy step 4 in the ambulatory BP 
group (19.2% versus 32.6%, p = 0.13) (Table 16). 
 
Table 16. Treatment status of the patients at the end of the study. 
Treatment step HBP group (n = 52) ABP group (n = 46) p-value 
Step 1 (CS 8 mg) 17.3 15.2 0.78 
Step 2 (CS 16 mg) 17.3 17.4 0.99 
Step 3 (CS 16 mg + HCTZ 12,5 mg) 46.2 34.8 0.25 
Step 4 (CS 16 mg + HCTZ 12,5 mg + FD 5 mg) 19.2 32.6 0.13 
Values expressed as percentage. CS, candesartan; HCTZ, hydrochlorothiazide; FD, felodipine; HBP, home blood 
Pressure; ABP, ambulatory blood pressure. 
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6 DISCUSSION 
6.1 Diagnosing hypertension with home blood pressure 
measurement (I) 
Values obtained with clinic BP measurements in a nation-wide population are 
significantly higher than those obtained with home measurements, and their 
agreement in diagnosing hypertension is moderate at best. Clinic BP slightly 
overestimates the prevalence of hypertension when compared to home BP (49% 
versus 43%), but no significant difference was observed in the share of treated 
hypertensives with good BP control (33% versus 29%). 
Mean clinic BP was 7.7/3.4 mmHg higher than mean home BP in this population, 
well in line with results from multinational meta-analyses [61, 62]. The mean 
difference and the 95% limits of agreement increased with BP. The relationship 
between clinic-home difference and higher BP has been shown in a recent meta-
analysis by Verberk but, in contrast to the present study, only for systolic BP among 
untreated hypertensive subjects [61]. However, the results of the meta-analysis are 
undermined by the fact that there were marked differences in the study cohorts and 
in the methods used for measuring clinic and home BP. According to the findings of 
the present study, the difference between home and clinic BP appears to be greater 
among hypertensive subjects, for whom precise BP measurement can more 
effectively prevent unnecessary treatment and costs.  
The worldwide prevalence of hypertension was 26% in the year 2000 using the 
recommended threshold of 140/90 mmHg [1]. In developed countries the control of 
hypertension is relatively poor as only 30–50% of treated hypertensives reach the 
target BP [158]. However, the population studies which these meta-analyses are 
based on have used conventional clinic BP measurements. Since home BP has a 
better prognostic accuracy than clinic BP the assessment of prevalence and control 
of hypertension at a population level would also be more accurate when based on 
home BP [87, 159]. The majority of studies assessing the agreement between home 
and clinic BP measurement have been performed on selected hypertensive 
populations or have used the same thresholds for elevated home and clinic BP [69, 
70]. Only two Japanese population-based studies (one community-based study and 
one nationwide study with only treated hypertensives) have assessed the control of 
BP with home and clinic measurements according to the current guidelines [88, 
160]. In the present study the prevalence of hypertension among the Finnish 45–74 
year-old population was slightly higher when defined with clinic instead of home 
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measurements. In Japan, the proportion of hypertensives assessed with home BP 
was similar to that assessed by clinic BP [88]. No significant differences in control 
rates were observed in Japan or in Finland when assessed by clinic or home BP 
[160]. The currently recommended 5 mmHg lower BP thresholds for home BP 
measurement therefore seem to work quite well [30, 42]. The control of 
hypertension assessed by home measurement appears to be better in Japan (45.3%) 
than in Finland (32.8%) [160]. These levels of control are far from excellent and 
indicate that poor BP control is not only a reflection of the white-coat effect, but also 
reveal a true lack of sufficient BP control and adherence to treatment. 
In this study, clinic BP was significantly higher in untreated hypertensives than in 
treated hypertensives, despite a similar home BP. This is in line with the findings of 
earlier studies showing that antihypertensive medication reduces, but does not 
eliminate the white-coat effect [88, 161, 162]. Some antihypertensive drugs have 
been reported to reduce the cardiovascular stress responses that clinic BP 
measurement incites [163]. A part of the reduction in the white-coat effect could 
also result from the treated subjects measuring their morning home BP before taking 
their medication at the trough while clinic BP, on the other hand, was measured 
during the day when the effect of the medication is at its peak. Thus, home BP 
values would be closer to the clinic BP values due to minimum and maximum 
effects of the treatment. Furthermore, treated hypertensives could be more 
accustomed to medical settings and exhibit a smaller alerting reaction in BP during 
clinic BP measurements. 
6.2 Diagnosing isolated clinic hypertension with home blood 
pressure measurements (II) 
This was the first study examining the prevalence and determinants of ICH on a 
nationwide level. The prevalence of ICH in the untreated Finnish adult population 
was 15.6%, and 37.5% among untreated subjects with elevated clinic BP. ICH was 
associated with mildly elevated systolic and diastolic BP, lower BMI, and non-
smoking status, but not with any psychosocial disorders. The metabolic 
cardiovascular risk factors of subjects with ICH were between those of the 
hypertensives and normotensives. 
Most of the previous studies have assessed the prevalence and determinants of ICH 
in selected groups of hypertensive subjects using ambulatory BP monitoring [74, 82-
86, 164]. Because of a selection bias, the prevalence of ICH at the population level 
cannot be estimated from data collected in those studies. The prevalence of ICH in 
the general untreated Finnish population was less than reported in most previous 
studies including only hypertensive subjects [74, 82, 83, 85, 164], but very close to 
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that of 12% reported in the untreated subjects of the Italian PAMELA study [78].  
The findings of this study support 12–15% to be very close to the true prevalence of 
ICH in a western adult population not treated for hypertension. In addition, the 
prevalence of ICH was 37.5% among untreated hypertensives. Thus, one patient in 
every third with newly diagnosed hypertension could be overdiagnosed as 
hypertensive in a screening situation. In Japan, the prevalence of ICH appears to be 
even higher, as 60% of the untreated hypertensive subjects had normal home BP 
values [88]. 
ICH was independently associated with mildly elevated systolic and diastolic BP, 
lower BMI, and non-smoking status. The probability of ICH increases with mildly 
elevated BP levels [83, 84, 86], because smaller differences between clinic and 
home BP are needed to meet the criteria for ICH. Therefore special attention should 
be focused on patients with mild to moderate hypertension before commencing 
antihypertensive medication. The association of ICH with a non-smoking status seen 
in this study has also been demonstrated in studies by Verdecchia [86] and Dolan 
[84]. A population-based study on elderly men by Björklund et al. has reported that 
a lower BMI characterized subjects with future development of ICH as compared to 
those with future sustained hypertension [80]. Also, in a study with 292 borderline 
hypertensives, subjects with ICH were more likely to weigh less [74]. Other studies, 
although with selected hypertensive study populations, have found no association 
between BMI and ICH [165, 166]. The BP-raising effects of smoking [167, 168] and 
BMI [74, 83, 84, 86] are well known, but the role of nonsmoking status as a marker 
of increased prevalence of ICH requires additional study. In any case, the findings of 
this study state that subjects with ICH tend to lead a slightly healthier way of life 
than sustained hypertensives by smoking less and having a lower BMI, which might 
also contribute to their lower BP levels. 
Many previous studies [74, 83, 84, 86] have demonstrated a higher prevalence of 
ICH in women, but no such difference was found in the present study. Again, these 
studies were performed on selected hypertensive individuals. In the PAMELA study 
(49% women), there were not significantly more women in the subjects with systolic 
(37% women) or diastolic (52% women) ICH [74, 82]. The present study and the 
PAMELA study both suggest that female gender is not associated with ICH in the 
general untreated population. Age has also been proposed as a determinant of ICH. 
However, the results from previously published studies with selected patients are 
very conflicting as ICH has been associated with younger age in two studies [84], 
with older age in one study [83, 86], and no association has been found in two 
studies [89-91, 169]. In the present study, no independent connection was observed 
between age and ICH, although the study population included only subjects aged 
45–74 years. 
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Our data do not support the notion that a specific personality structure may 
predispose some individuals to ICH. Previous studies have also concluded that 
subjects with ICH did not show abnormal hostility, anxiety, or depression, when 
compared to subjects with sustained hypertension [89-91, 169]. The study by 
Muneta et al. suggested that subjects with ICH tend to suppress their own emotions 
and become over-adaptive to their surroundings [89]. Crippa et al. suggested that 
ICH might be associated with healthcare-related fears and emotional instability 
[169]. However, the sample sizes of all these previous studies have been rather small 
(70-218 patients) and have only included patients with previously diagnosed 
hypertension. Although ICH does not seem to be associated with any psychological 
characteristic, subjects with ICH might still have a behavioral trait of over-reactivity 
to stress. 
The demographic, clinic and metabolic characteristics of subjects with ICH were 
mostly between those of the hypertensive and normotensive subjects. Subjects with 
ICH had a lower BP, a lower BMI and were younger than sustained hypertensives. 
Otherwise, their risk profile was similar to the subjects with sustained hypertension 
in terms of gender distribution, diabetes prevalence, serum fasting glucose, and 
serum lipid profile. Normotensives differed from sustained hypertensives more 
noticeably in all of these previously listed risk factors. Normotensive subjects were 
also younger, and had a lower BP, serum total cholesterol and triglyceride level than 
subjects with ICH. The data from this study suggest that subjects with ICH do not 
differentiate from sustained hypertensives where metabolic cardiovascular risk 
factors are concerned but they lead healthier lives than the sustained hypertensives 
do. The evidence that subjects with ICH are at a higher risk for future permanent 
hypertension [170, 171] and cardiovascular events [112, 127-129] is in line with 
these findings. Therefore, it is important to assess their BP, risk factor status and 
lifestyle periodically. 
6.3 Association between home blood pressure and end-organ 
damage (III-V) 
Our results extend previous evidence suggesting that home BP has a more important 
role in predicting target organ damage than does clinic BP [172-175]. In this study 
with a representative sample of a nationwide adult population aged 45–74 years it 
was shown that home BP has a stronger association with carotid IMT, ECG-LVH, 
and PWV than clinic BP, even for a very low number of home measurements. The 
association between home BP and ECG-LVH or PWV becomes slightly stronger 
with an increasing number of home measurements, but not for carotid IMT. Carotid 
IMT is independently associated with age, home BP, serum triglycerides, male 
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gender, smoking, diabetes, and LDL-cholesterol. PWV is independently associated 
with home BP, age, and diabetes, with home BP being the most important factor 
affecting arterial stiffness. 
Carotid IMT is an important predictor for cardiovascular morbidity and mortality, 
and the rate of carotid IMT thickening can be attenuated with antihypertensive 
medication [176, 177]. Carotid IMT is therefore an important factor in assessing 
cardiovascular risk in a hypertensive patient. Consequently, the treating physician 
should use a BP measurement method that provides a good image of the patient’s 
true BP level, and also has a strong correlation with carotid IMT. Home BP fulfills 
these requirements, as demonstrated by this study. The factors associated with IMT 
presented in this study are well in line with findings of other studies. Previous 
population studies, such as the Atherosclerosis Risk in Communities (ARIC) study, 
have established an association between carotid IMT and cardiovascular risk factors 
such as age, smoking, LDL-cholesterol, diabetes, triglycerides and BP [178, 179]. 
Many studies, including ours, have suggested that BP is one of the most important 
factors affecting carotid IMT [180]. Considering that most of the previous 
population studies assessing risk factors for carotid atherosclerosis have used 
conventional clinic BP measurement as a method for measuring BP, the significance 
of BP in the pathogenesis of atherosclerosis might be even more important than 
previously assumed. 
Arterial PWV has been identified as a marker of elastic artery stiffening, and also a 
strong independent predictor of cardiovascular mortality [181]. Arterial stiffness and 
hypertension appear to interact in a bidirectional manner. On the one hand, untreated 
hypertension accelerates the rate of large artery stiffness and thus perpetuates a 
vicious cycle of accelerated hypertension and further increases in large artery 
stiffness, and on the other hand, arterial stiffness has been identified as a predictor of 
future hypertension in normotensive individuals [182]. The factors associated with 
PWV presented in this study are in accord with the findings of other studies. 
Progression of arterial stiffness is more pronounced in older subjects, and age has 
been generally considered to be the most important factor affecting PWV. However, 
BP elevation promotes accelerated vascular aging [183]. In this study, home BP was 
actually a slightly more important determinant for increased PWV than age. 
Considering that most of the previous studies assessing risk factors for arterial 
stiffness have used conventional clinic BP measurement as a method for measuring 
BP, the role of BP in the pathogenesis of arterial stiffness and vascular aging might 
be even more important than previously thought. As in this study, diabetes and 
insulin resistance have been previously associated with increased arterial 
stiffness.[184] Cholesterol levels, however, seem to play a smaller part in the 
pathogenesis of arterial stiffness [185]. 
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Left ventricular hypertrophy (LVH) is an independent risk factor for increased 
cardiovascular mortality [186]. LVH is linearly related to the level of BP, and can 
eventually lead to congestive heart failure, of which approximately half is caused by 
hypertension [127, 187]. Some studies have already reported that home BP is more 
strongly associated with the degree of LVH as determined by echocardiography [14, 
59]. However, echocardiography is not widely available and despite a poor 
sensitivity, ECG is often the only method available for assessing LVH in the 
hypertensive patient, especially in typical primary care settings. Home BP measured 
during one week had a stronger association with ECG-LVH than did clinic BP in 
this study. Home and clinic hypertensives had an equally high risk for ECG-LVH. 
The currently recommended 5 mmHg lower BP thresholds for home BP 
measurement therefore seem to be appropriate, at least in terms of ECG-LVH 
prevalence and risk [60]. The prevalence and risk of ECG-LVH were slightly, but 
not significantly higher in subjects who had elevated home and clinic BP. This 
finding is in line with the results of the PAMELA study, as the overall ability to 
predict death was increased by the combination of clinic and home values [69, 188]. 
The association between home BP and hypertensive end-organ damage increased 
slightly with an increasing number of measurements in the present study. However, 
home BP was more closely associated with end-organ damage than was clinic BP 
even when only the first two measurements were used. More importantly, home BP 
also seems to be a stronger predictor of cardiovascular risk than clinic BP as the two 
initial home BP measurements were more closely associated with cardiovascular 
risk than the two initial clinic BP measurements in the Ohasama study [53]. In 
addition, in the PAMELA study only two home readings were obtained, and these 
were stronger predictors of cardiovascular risk than were six clinic measurements 
[51]. The benefits of home BP measurement are thus not based solely on the 
statistical advantages associated with the availability of repeated measurements, but 
also on the information obtained outside of the clinical setting. This conclusion is 
also supported by the cross-sectional findings of the present study. 
6.4 Proposed schedule for home blood pressure measurement (I, 
III–V) 
The current ESH guidelines recommend measuring home BP twice every morning 
and evening for one week and discarding the first day of measurement, while  the 
North American guidelines advise taking three readings on one occasion every 
morning and evening, but do not mention for how many days [30, 42]. The 
conflicting guidelines demonstrate that agreement over the optimal schedule for 
home BP measurement has not yet been reached. A schedule for home BP 
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measurement is now proposed based on findings from the present and previous 
studies. 
In this study, home BP decreased noticeably between the first and second days of 
measurement and stabilized from the third day onwards. The association between 
end-organ damage and home BP increased slightly with the number of home 
measurements, but most of this increase occurred during the first three days of 
measurement. It is therefore proposed that home BP measurement should be 
performed for a minimum of three days.  
It has been previously demonstrated in the Ohasama study that the predictive value 
for stroke risk associated with home BP increases progressively within the range of 
1–14 measurements performed during one week without any clear threshold [55]. 
The findings of the present study comparing the association between ECG-LVH or 
PWV and home BP in the Finn-HOME population are in accord with the findings of 
the Ohasama study as the correlation increased slightly but steadily over a one-week 
period. However, home BP was measured twice on each occasion and 28 
measurements were obtained. No significant increase in the correlation between end-
organ damage and home BP occurred after the sixth day of measurement.  Seven 
days of measurement, as recommended by the ESH guidelines, therefore appear to 
be sufficient. 
Mean home BP of the initial monitoring day produced the highest and most variable 
values.  This phenomenon has been shown in some [49, 131] but not all [53] studies 
on selected hypertensive populations, and it appears to be present also in the 
population as a whole [42, 53]. The plateau level that is reached with an increasing 
number of home BP measurements, as the patient becomes acquainted with home 
measurement, could therefore best represent the subjects’ “true” BP level. The ESH 
guidelines recommend discarding home BP values obtained on the first day of 
measurement because of their instability [42]. However, results from the Ohasama 
study suggest that discarding the first day of measurements could not necessarily be 
applicable from the view point of prognostic significance [53]. In addition, the first 
days of measurement did not show a weaker correlation with end-organ damage than 
did the other days in the present study. Further prognostic research is therefore 
warranted to clarify whether BP values obtained on the first day of home 
measurement should be discarded before this policy can be recommended. 
In accordance with previously published studies, small differences in evening and 
morning home BP existed in the Finnish population [55, 56]. Evening BP was 
slightly higher in subjects who were not on antihypertensive medication, but this 
difference was non-existent for systolic BP and reversed for diastolic BP among 
treated hypertensives. Most antihypertensive medications are administered once a 
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day, usually in the morning. Home BP was measured in the morning at trough when 
the effect of the medication is at its lowest, which explains the observed difference 
between treated and untreated subjects. Because of the diurnal variation in BP, home 
measurements in the morning and in the evening are recommended to obtain a 
thorough image of the average BP and to evaluate the round-the-clock efficacy of 
antihypertensive medication and the differences between various antihypertensive 
drugs [59]. 
Almost all guidelines recommend two or three consecutive measurements on each 
occasion [30, 42]. This recommendation is based on the evidence that regression to 
the mean during consecutive measurements on each occasion is frequently observed 
even after long term monitoring [49]. In accordance with the findings from previous 
studies, the second measurement produced on average 3/1 mmHg lower BP values 
than the first measurement in the present study. The Japanese Society of 
Hypertension guidelines for self-monitoring of BP at home recommend at least one 
measurement on each occasion without denying that multiple measurements might 
be of value, but this recommendation is based mostly on speculation that it would be 
more convenient and result in better compliance [189]. Unfortunately, no prognostic 
data on this matter is yet available since the two largest epidemiological studies have 
been performed with only one measurement on each occasion [51, 53]. Until such 
data become available, home BP should be measured twice on each occasion 
because of the regression to the mean effect. 
In conclusion, based on the results from this and previous studies, measurement of 
BP twice in the morning and in the evening preferably for a period of seven days, or 
for at least three days, is recommended for obtaining a thorough image of a patient’s 
true BP level. More prognostic data are still needed before discarding the 
measurements performed on the first day can be recommended. 
6.5 Home blood pressure measurement in the adjustment of 
antihypertensive therapy (VI) 
Antihypertensive treatment based on either home BP measurement or ambulatory 
BP monitoring while using the same target pressure (diastolic BP ≤ 80 mmHg) led 
to equally good BP control with both methods in patients with mild to moderate 
hypertension. Drug therapy was tended to be more intensive in the ambulatory BP 
group and slightly more patients reached the target pressure in the home BP group, 
but these differences were non-significant. No studies have been published earlier 
that have directly compared antihypertensive treatment based on home BP with 
ambulatory BP. 
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The small difference in BP changes between home and ambulatory BP groups at the 
end of the study were slightly in favor of the ambulatory BP monitoring group, and 
these differences might have become statistically significant if a larger number of 
patients had been included. The clinical significance of these differences (range 0.6–
2.6 mmHg) would nevertheless be relatively small because a 1 mmHg lower systolic 
BP would involve, for example, an approximately 5.6% lower risk for stroke in 
younger adults, dropping to a 1.8% lower risk in adults aged 75 years and over 
[190]. The small between-group difference in BP changes at the end of the follow-
up period is most likely explained by the difference in the BP guiding treatment at 
randomization. Diastolic ambulatory daytime BP was 3.8 mmHg higher in the 
ambulatory BP group than the diastolic home BP in the home BP group at 
randomization, which probably resulted in slightly more intensive treatment and a 
greater reduction in BP. Although BP decreased more in the ambulatory group, a 
larger share of the patients reached the target BP in the home BP group because the 
difference between target BP and BP guiding treatment was smaller at 
randomization. 
The marked difference in clinic and home BP values at baseline while using the 
same target pressure was the main limitation in previous studies that have compared 
antihypertensive treatment based on home or clinic BP [124, 125]. For example, in 
the 2004 THOP study the diastolic BP guiding treatment was 9.5 mmHg higher at 
randomization for the clinic BP group than for the home BP group using the same 
target BP [124]. This unsurprisingly led to more intensive drug therapy and greater 
BP decrease in the office BP group. In the present study, when comparing home and 
ambulatory BP, the problem of a difference in BP values still exists, but to a much 
lesser extent. More importantly, current guidelines recommend the same treatment 
threshold for home and daytime ambulatory BP [30, 42]. A target pressure which is 
5 mmHg higher should be used for clinic BP than for home BP. This was not taken 
into account in the THOP and HOMERUS trials and partially nullifies their results 
[30, 42, 124, 125]. 
Home monitoring has many of the benefits of ambulatory BP monitoring, and is even 
better in some aspects (Table 2). Low compliance to treatment is one of the most 
important causes for poor control of hypertension. Home measurement of BP allows 
the patient be more actively involved in their treatment, thereby improving adherence 
to treatment [120, 121]. Ambulatory monitoring causes discomfort and disturbance of 
sleep and is greatly disliked by patients, unlike home BP monitoring which is the most 
acceptable method for patients, when compared to ambulatory monitoring, 
measurement by a doctor or a nurse, or self-measurement in a room provided by the 
hospital [119]. Home measurement of BP is also relatively inexpensive and feasible 
when compared to ambulatory monitoring and can be easily performed in the basic 
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healthcare system. A meta-analysis of 18 randomized controlled trials by Cappuccio et 
al. reported that using home BP measurement rather than office BP measurements in 
the healthcare system resulted in better BP control (4.2/2.4 mmHg, and 2.2/1.9 mmHg, 
when allowing for publication bias) and greater achievement of BP targets (10% 
greater proportion on target) [118]. A recent study in a Finnish primary care setting 
also confirmed these findings [191]. Home BP should therefore be considered as an 
attractive option for measuring BP and even as the method of choice when guiding 
antihypertensive treatment in the primary care setting. 
6.6 Study limitations 
6.6.1 Studies I–V 
First, clinic BP, although very meticulously assessed, was measured in a screening 
situation on one day only and duplicate home BP readings were performed twice daily 
for seven days. Therefore, the possibility that clinic BP values over multiple days could 
have resulted in values closer to home BP cannot be excluded. However, in real life, 
home BP measurement always produces a larger number of BP readings than clinic 
measurement. Furthermore, as demonstrated by the Ohasama study and this study, the 
benefits of home BP measurement are not based solely on the statistical advantages 
associated with the availability of repeated measurements, but also on obtaining 
information outside of the clinical setting with even a few home BP measurements [53, 
54]. Second, clinic BP was measured with a mercury sphygmomanometer and home BP 
with an automated oscillometric device. On the other hand, clinic BP is still widely 
measured with a mercury sphygmomanometer in Finland, so this also reflects reality. In 
addition, all large epidemiological studies, on which the prognostic evidence of clinic BP 
is based, have used conventional mercury sphygmomanometers. Third, participants in 
the Finn-HOME substudy had a 2.3 mmHg lower systolic BP than the non-participants, 
which might have resulted in a small underestimation in the prevalence of hypertension. 
Fourth, because of the cross-sectional nature of this study, no cause-effect relationships 
can be drawn from the findings, and more outcome studies are needed. 
6.6.2 Study VI 
First, this study of 110 patients spanned a follow-up period of 24 weeks and the 
findings may require further validation in larger, long-term prospective studies. 
Second, if the study would have included a clinic measurement group, there would 
have been a possibility to compare all three methods of BP measurement in the 
management of hypertension. 
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7 CONCLUSIONS 
Home BP is 8/3 mmHg lower than clinic BP in a representative Finnish adult 
population. This significant difference between home and clinic BP becomes even 
larger at higher levels of BP. The agreement between home and clinic BP in 
diagnosing hypertension according to the current guidelines is moderate at best. 
Clinic BP slightly overestimates the prevalence of hypertension when compared to 
home BP. 
Home BP decreases noticeably between the first and second days of measurement 
and stabilizes from the third day onwards. Morning and evening variation in home 
BP exists and should be taken into consideration when measuring home BP or 
assessing the round-the-clock efficacy of antihypertensive treatment. 
The prevalence of ICH, or “white-coat hypertension”, in this population not treated 
for hypertension was 16%. Among untreated hypertensives, the prevalence of ICH 
was 38%. Thus, hypertension could be overdiagnosed in every third patient in a 
screening situation. This relatively high prevalence of ICH emphasizes the 
importance of identifying these subjects. 
The demographic, clinical and metabolic characteristics of subjects with ICH were 
mostly between those of the hypertensive and normotensive subjects. Physicians 
should suspect ICH when a hypertensive patient has mildly elevated systolic or 
diastolic BP, low BMI, and does not smoke. Physicians should disassociate the 
diagnosis of ICH from specific psychological symptoms, but should remember that 
subjects with ICH are at an increased risk for the development of cardiovascular 
disease and require periodic follow-ups. 
Home BP is one of the most important determinants of cardiovascular end-organ 
damage and is more strongly associated with end-organ damage than is clinic BP, 
even with a low number of home measurements. 
Measurement of BP twice in the morning and evening preferably for a period of 
seven days, or for at least three days, is recommended for obtaining a thorough 
image of a patient’s true BP level. 
The present findings suggest that adjustment of antihypertensive treatment based on 
home BP measurement is effective as it led to equally good BP control as did 
ambulatory BP monitoring, which has been considered by many as the gold 
standard. 
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Additional large-scale prognostic population studies are still needed to provide 
further evidence of home BP’s prognostic superiority over clinic BP and to 
determine a definitive schedule for home BP measurement and the exact diagnostic 
and treatment thresholds for home-measured BP. This information should become 
available from the follow-up phase of the Finn-HOME study. Furthermore, larger 
follow-up studies using currently recommended treatment thresholds are needed to 
provide further confirmation of the benefits of home BP measurement in guiding 
antihypertensive treatment as compared with other methods. 
On the basis of the results from this study and data from previous studies, it can be 
concluded that home BP measurement offers specific advantages over conventional 
clinic measurement. Home monitoring of BP is a convenient, accurate, and widely 
available option and may become the method of choice for diagnosing and treating 
hypertension. A paradigm shift is needed in BP measurement as evidence-based 
medicine suggests that clinic BP measurement should mainly be restricted for 
screening purposes. 
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